var title_f9_22_9568="US ovarian ca incidence age race";
var content_f9_22_9568=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F83400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F83400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    US ovarian cancer incidence by age and race/ethnicity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 492px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cancer sties include invasive cases only unless otherwise noted.",
"    <br>",
"     Hispanics and Non-Hispanics are not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Surveillance, Epidemiology and End Results (SEER). National Cancer Institute. More information available at:",
"      <a href=\"file://seer.cancer.gov/\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"       file://seer.cancer.gov/",
"      </a>",
"      .",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_22_9568=[""].join("\n");
var outline_f9_22_9568=null;
var title_f9_22_9569="Normal versus refluxing ureterovesical junctions";
var content_f9_22_9569=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal versus refluxing ureterovesical junctions",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Pediatric Nephrology, Avner ED, Harmon WE, Niaudet P (Eds), Lippincott, Philadelphia, PA 2004. p.1028.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_22_9569=[""].join("\n");
var outline_f9_22_9569=null;
var title_f9_22_9570="Gastrointestinal stromal tumor CPC Endosc";
var content_f9_22_9570=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Gastrointestinal stromal tumor (GIST)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of an actively oozing 20 mm by 30 mm submucosal mass in the stomach body (left panel). Bleeding was controlled by injection of a 1:10,000 epinephrine solution and bipolar electrocautery (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kenneth Falchuk, MD and Andres Gelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_22_9570=[""].join("\n");
var outline_f9_22_9570=null;
var title_f9_22_9571="Patient information: Arthritis and exercise (The Basics)";
var content_f9_22_9571=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16160\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/2/40995\">",
"         Lateral neck flexion",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/12/28864\">",
"          Knee chest stretch",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/2/31777\">",
"           Hamstring stretch",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/7/43121\">",
"            Gastrocnemius stretch",
"           </a>",
"           <li>",
"            <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/13/44242\">",
"             Shoulder ROM with cane",
"            </a>",
"            <li>",
"             <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/36/33345\">",
"              Wrist extensor stretch",
"             </a>",
"             <li>",
"              <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/47/10992\">",
"               Finger flexion/extension",
"              </a>",
"              <li>",
"               <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/41/26256\">",
"                Press up",
"               </a>",
"               <li>",
"                <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/45/24287\">",
"                 Trunk lift",
"                </a>",
"                <li>",
"                 <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/48/20230\">",
"                  Forward step up",
"                 </a>",
"                </li>",
"               </li>",
"              </li>",
"             </li>",
"            </li>",
"           </li>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?8/7/8307\">",
"         Patient information: Ankylosing spondylitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/39/20083\">",
"         Patient information: Exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/3/43058\">",
"         Patient information: Osteoarthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?16/31/16883\">",
"         Patient information: Rheumatoid arthritis (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/38/19045\">",
"         Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/62/28645\">",
"         Patient information: Arthritis and exercise (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?7/42/7844\">",
"         Patient information: Exercise (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/29/21975\">",
"         Patient information: Osteoarthritis treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?23/44/24264\">",
"         Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Arthritis and exercise (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/arthritis-and-exercise-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H31048474\">",
"      <span class=\"h1\">",
"       Should people with arthritis exercise?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. People with arthritis should exercise. In the long run, regular exercise can help reduce the pain of arthritis, even though exercising might be painful at first.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31048481\">",
"      <span class=\"h1\">",
"       What should I do before starting an exercise program?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Before starting an exercise program, talk with your doctor or nurse. Ask him or her if there are any exercises or sports you should or should not do. You can also ask him or her if you should see a physical therapist (exercise expert) before you start to exercise.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31048488\">",
"      <span class=\"h1\">",
"       What kind of exercise program should I do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That&rsquo;s up to you. But the exercise program you choose should work in 2 ways. It should:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Make your muscles stronger &mdash; Doing this can reduce pain and help to protect your joints and make them stronger. One way to make muscles stronger is to use weights or weight machines.",
"       </li>",
"       <li>",
"        Increase your heart rate and breathing &mdash; Doing this can improve your heart health and lower your blood pressure. Doctors recommend that you increase your heart rate with low-impact activities, such as walking, biking, or swimming. Low-impact activities are easier on your joints than high-impact activities. Doctors do not usually recommend high-impact activities, such as running, for people with arthritis.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31048495\">",
"      <span class=\"h1\">",
"       How much should I exercise?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You should try to exercise about 30 to 40 minutes a day, on most days of the week. If you can&rsquo;t exercise for 30 to 40 minutes at a time, break your exercise up into shorter sessions.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31048502\">",
"      <span class=\"h1\">",
"       How can I exercise safely if I have arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have arthritis, you can exercise safely by following these tips:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Start slowly and increase your exercise program slowly",
"       </li>",
"       <li>",
"        Take 10 to 15 minutes to warm up before exercising &mdash; To warm up, you can walk slowly, march in place, or stretch your muscles.",
"       </li>",
"       <li>",
"        Start with lighter weights and slowly increase them (if you use weights)",
"       </li>",
"       <li>",
"        Make sure to cool down for about 5 minutes after exercising &mdash; To cool down, you can walk slowly or stretch your muscles.",
"       </li>",
"       <li>",
"        Protect your joints when you exercise by:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Walking on a flat surface, if you have hip, knee, foot, or ankle problems",
"       </li>",
"       <li>",
"        Wearing shoes that support and cushion your feet",
"       </li>",
"       <li>",
"        Paying attention to pain &mdash; If you have pain, stop or change what you are doing.",
"       </li>",
"       <li>",
"        Avoiding movements that twist your joints",
"       </li>",
"       <li>",
"        Wearing a knee brace or other support, if your doctor or nurse recommends it",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31048509\">",
"      <span class=\"h1\">",
"       What exercises can help with different kinds of arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Certain exercises can help with different kinds of arthritis and different symptoms.",
"     </p>",
"     <p>",
"      For osteoarthritis and most other types of arthritis, it&rsquo;s important to move your joints every day, even if they hurt. For example, you should try to bend and straighten your knees a few times a day, even if you have arthritis pain in your knees.",
"     </p>",
"     <p>",
"      To help reduce stiffness in the morning, try these exercises before going to sleep: (",
"      <a class=\"graphic graphic_picture graphicRef79565 \" href=\"UTD.htm?40/2/40995\">",
"       picture 1",
"      </a>",
"      ); (",
"      <a class=\"graphic graphic_picture graphicRef64407 \" href=\"UTD.htm?28/12/28864\">",
"       picture 2",
"      </a>",
"      ); (",
"      <a class=\"graphic graphic_picture graphicRef57600 \" href=\"UTD.htm?31/2/31777\">",
"       picture 3",
"      </a>",
"      ); (",
"      <a class=\"graphic graphic_picture graphicRef52289 \" href=\"UTD.htm?42/7/43121\">",
"       picture 4",
"      </a>",
"      ); (",
"      <a class=\"graphic graphic_picture graphicRef75309 \" href=\"UTD.htm?43/13/44242\">",
"       picture 5",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      To help with hand and wrist symptoms of rheumatoid arthritis, try these hand and wrist exercises: (",
"      <a class=\"graphic graphic_picture graphicRef81293 \" href=\"UTD.htm?32/36/33345\">",
"       picture 6",
"      </a>",
"      ); (",
"      <a class=\"graphic graphic_picture graphicRef53043 \" href=\"UTD.htm?10/47/10992\">",
"       picture 7",
"      </a>",
"      ).",
"     </p>",
"     <p>",
"      To help with back and hip symptoms of ankylosing spondylitis, try these back and hip exercises: (",
"      <a class=\"graphic graphic_picture graphicRef61695 \" href=\"UTD.htm?25/41/26256\">",
"       picture 8",
"      </a>",
"      ); (",
"      <a class=\"graphic graphic_picture graphicRef58290 \" href=\"UTD.htm?23/45/24287\">",
"       picture 9",
"      </a>",
"      ); (",
"      <a class=\"graphic graphic_picture graphicRef69481 \" href=\"UTD.htm?19/48/20230\">",
"       picture 10",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31048516\">",
"      <span class=\"h1\">",
"       What if I have pain when I exercise?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have pain when you exercise, talk with your doctor or nurse about what you can do. When you first start to exercise, some aching or soreness is normal. If your pain is severe or lasts more than 2 hours after exercising, you might need to change your exercise program or the way you do your exercises.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31048523\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=see_link\">",
"       Patient information: Osteoarthritis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=see_link\">",
"       Patient information: Rheumatoid arthritis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/7/8307?source=see_link\">",
"       Patient information: Ankylosing spondylitis (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=see_link\">",
"       Patient information: Exercise (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=see_link\">",
"       Patient information: Osteoarthritis treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=see_link\">",
"       Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28645?source=see_link\">",
"       Patient information: Arthritis and exercise (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=see_link\">",
"       Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"       Patient information: Exercise (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?9/22/9571?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16160 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9662981F41-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_22_9571=[""].join("\n");
var outline_f9_22_9571=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31048474\">",
"      Should people with arthritis exercise?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31048481\">",
"      What should I do before starting an exercise program?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31048488\">",
"      What kind of exercise program should I do?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31048495\">",
"      How much should I exercise?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31048502\">",
"      How can I exercise safely if I have arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31048509\">",
"      What exercises can help with different kinds of arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31048516\">",
"      What if I have pain when I exercise?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31048523\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16160\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/2/40995\">",
"      Lateral neck flexion",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/12/28864\">",
"       Knee chest stretch",
"      </a>",
"      <li>",
"       <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/2/31777\">",
"        Hamstring stretch",
"       </a>",
"       <li>",
"        <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/7/43121\">",
"         Gastrocnemius stretch",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/13/44242\">",
"          Shoulder ROM with cane",
"         </a>",
"         <li>",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/36/33345\">",
"           Wrist extensor stretch",
"          </a>",
"          <li>",
"           <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/47/10992\">",
"            Finger flexion/extension",
"           </a>",
"           <li>",
"            <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/41/26256\">",
"             Press up",
"            </a>",
"            <li>",
"             <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/45/24287\">",
"              Trunk lift",
"             </a>",
"             <li>",
"              <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/48/20230\">",
"               Forward step up",
"              </a>",
"             </li>",
"            </li>",
"           </li>",
"          </li>",
"         </li>",
"        </li>",
"       </li>",
"      </li>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/7/8307?source=related_link\">",
"      Patient information: Ankylosing spondylitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=related_link\">",
"      Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/62/28645?source=related_link\">",
"      Patient information: Arthritis and exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=related_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=related_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/3/43058?source=related_link\">",
"      Patient information: Osteoarthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/29/21975?source=related_link\">",
"      Patient information: Osteoarthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_22_9572="Diabetes mellitus type 2: Overview";
var content_f9_22_9572=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Diabetes mellitus type 2: Overview (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/22/9572/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/22/9572/contributors\" id=\"au5149\">",
"       David K McCulloch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/22/9572/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/22/9572/contributors\" id=\"se6384\">",
"       David M Nathan, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?9/22/9572/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/22/9572/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?9/22/9572?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     Type 2 diabetes mellitus is a disorder that disrupts the way your body uses glucose (sugar).",
"    </p>",
"    <p>",
"     All the cells in your body need sugar to work normally. Sugar gets into the cells with the help of a hormone called insulin. If there is not enough insulin, or if the body stops responding to insulin, sugar builds up in the blood. This is what happens to people with diabetes mellitus.",
"    </p>",
"    <p>",
"     There are two different types of diabetes mellitus. In type 1 diabetes mellitus, the problem is that the pancreas (an organ in the abdomen) does not make enough insulin. In type 2 diabetes mellitus, the pancreas does not make enough insulin (",
"     <a class=\"graphic graphic_figure graphicRef53979 \" href=\"UTD.htm?12/2/12325\">",
"      figure 1",
"     </a>",
"     ), the body becomes resistant to normal or even high levels of insulin, or both. This causes high blood glucose (blood sugar) levels, which can cause problems if untreated. In the United States, Canada, and Europe, about 90 percent of all people with diabetes have type 2 diabetes.",
"    </p>",
"    <p>",
"     Type 2 diabetes is a chronic medical condition that requires regular monitoring and treatment throughout your life. Treatment includes lifestyle changes, self-care measures, and sometimes medications. Fortunately, these treatments can keep blood sugar levels close to normal and minimize the risk of developing complications.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      THE IMPACT OF DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Being diagnosed with type 2 diabetes can be a frightening and overwhelming experience, and you likely have questions about why it developed, what it means for your long-term health, and how it will affect your everyday life.",
"    </p>",
"    <p>",
"     For most people, the first few months after being diagnosed are filled with emotional highs and lows. If you have just been diagnosed with diabetes, you and your family should use this time to learn as much as possible so that caring for your diabetes (including testing your blood sugar, going to medical appointments, and taking your medications) becomes a part of your daily routine. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"      \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     In addition, you should talk to your doctor or nurse about resources that are available for medical as well as psychological support. These may include group classes, meetings with a nutritionist, social worker, or nurse educator, and other educational resources such as books, web sites, or magazines. Several of these resources are listed below (see",
"     <a class=\"local\" href=\"#H18\">",
"      'Where to get more information'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     Despite the risks associated with type 2 diabetes, most people can lead active lives and continue to enjoy the foods and activities that they previously enjoyed. Diabetes does not mean an end to \"special occasion\" foods like birthday cake, and most people with diabetes can enjoy exercise in almost any form. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/32/31239?source=see_link\">",
"      \"Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/60/6083?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      CAUSES OF TYPE 2 DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Type 2 diabetes is thought to be caused by a combination of genetic and environmental factors. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link\">",
"      \"Pathogenesis of type 2 diabetes mellitus\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link\">",
"      \"Prediction and prevention of type 2 diabetes mellitus\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Genetic causes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many people with type 2 diabetes have a family member with either type 2 diabetes or other medical problems associated with diabetes, such as high cholesterol levels, high blood pressure, or obesity.",
"    </p>",
"    <p>",
"     The lifetime risk of developing type 2 diabetes is 5 to 10 times higher in first-degree relatives (sister, brother, son, daughter) of a person with diabetes compared to a person with no family history of diabetes.",
"    </p>",
"    <p>",
"     The likelihood of developing type 2 diabetes is greater in certain ethnic groups, such as people of Hispanic, African, and Asian descent.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Environmental conditions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Environmental factors such as what you eat and how active you are, combined with genetic causes, affect the risk of developing type 2 diabetes.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;A small number (about 3 to 5 percent) of pregnant women develop diabetes during pregnancy, called \"gestational diabetes.\" Gestational diabetes is similar to type 2 diabetes, but usually resolves after the woman delivers her baby. Women who have gestational diabetes are at increased risk for developing type 2 diabetes later in life. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/13/32979?source=see_link\">",
"      \"Patient information: Gestational diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      TYPE 2 DIABETES DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     The diagnosis of diabetes is based upon your symptoms and the results of blood tests. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link\">",
"      \"Diagnosis of diabetes mellitus\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Before being diagnosed with type 2 diabetes, most people have no symptoms at all. In those who do have symptoms, the most common include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Needing to urinate frequently",
"      </li>",
"      <li>",
"       Feeling thirsty",
"      </li>",
"      <li>",
"       Blurred vision",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Laboratory tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several blood tests are used to measure blood glucose levels, the primary test for diagnosing diabetes.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Random blood sugar test &mdash; For a random blood sugar test, you can have blood drawn at any time throughout the day, regardless of when you last ate. If your blood sugar is 200",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (11.1",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"       or higher and you have symptoms of high blood sugar (see",
"       <a class=\"local\" href=\"#H8\">",
"        'Symptoms'",
"       </a>",
"       above), it is likely that you have diabetes.",
"      </li>",
"      <li>",
"       Fasting blood sugar test &mdash; A fasting blood sugar test is a blood test done after not eating or drinking for 8 to 12 hours (usually overnight). A normal fasting blood sugar level is less than 100",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (5.55",
"       <span class=\"nowrap\">",
"        mmol/L).",
"       </span>",
"      </li>",
"      <li>",
"       Hemoglobin A1C test &mdash; The \"A1C\" blood test measures your average blood sugar level over the past two to three months. Normal values for A1C are 4 to 6 percent. The A1C test can be done at any time of day (before or after eating).",
"      </li>",
"      <li>",
"       Oral glucose tolerance test &mdash; Oral glucose tolerance testing (OGTT) is a test that involves drinking a special glucose solution (usually orange or cola flavored). Your blood sugar level is tested before you drink the solution, and then again one and two hours after drinking it.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Criteria for diagnosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;The following criteria are used to classify your blood sugar levels as normal, increased risk (blood sugar levels that are higher than normal and indicate a risk of future diabetes), or diabetes.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Normal",
"     </span>",
"     &nbsp;&mdash;&nbsp;Fasting blood sugar less than 100",
"     <span class=\"nowrap\">",
"      mg/dL",
"     </span>",
"     (5.55",
"     <span class=\"nowrap\">",
"      mmol/L).",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Categories of increased risk",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Impaired",
"       fasting glucose is defined as a fasting blood sugar level between 100 and 125",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (5.6 to 6.9",
"       <span class=\"nowrap\">",
"        mmol/L).",
"       </span>",
"      </li>",
"      <li>",
"       Impaired glucose tolerance is defined as a blood sugar level of 140 to 199",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       two hours after an oral glucose tolerance test.",
"      </li>",
"      <li>",
"       A1C &mdash; persons with 5.7 to 6.4 percent are at highest risk, although there is a continuum of increasing risk across the entire spectrum of subdiabetic A1C levels.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     At least 50 percent of people with impaired glucose tolerance eventually develop type 2 diabetes. Even if they don't develop diabetes, these people are at increased risk of heart disease. Impaired glucose tolerance is very common; about 11 percent of all people between the ages of 20 and 74 have impaired glucose tolerance.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Diabetes mellitus",
"     </span>",
"     &nbsp;&mdash;&nbsp;A person is considered to be diabetic if he or she has one or more of the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Symptoms of diabetes (see",
"       <a class=\"local\" href=\"#H8\">",
"        'Symptoms'",
"       </a>",
"       above)&nbsp;",
"       <strong>",
"        and",
"       </strong>",
"       a random blood sugar of 200",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (11.1",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"       or higher",
"      </li>",
"      <li>",
"       A fasting blood sugar level of 126",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (7.0",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"       or higher",
"      </li>",
"      <li>",
"       A blood sugar of 200",
"       <span class=\"nowrap\">",
"        mg/dL",
"       </span>",
"       (11.1",
"       <span class=\"nowrap\">",
"        mmol/L)",
"       </span>",
"       or higher two hours after an oral glucose tolerance test",
"      </li>",
"      <li>",
"       An A1C of 6.5 percent or higher",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The blood tests must be repeated on another day to confirm the diagnosis of diabetes.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Type 1 versus type 2 diabetes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Doctors can usually tell whether a person has type 1 or type 2, but there are situations when the diagnosis is difficult to determine. In such cases, doctors often run additional blood tests.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      TYPE 2 DIABETES TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     A full discussion of the treatment for type 2 diabetes is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/37/36436?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/28/18886?source=see_link\">",
"      \"Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=see_link\">",
"      \"Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      TYPE 2 DIABETES COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Complications of type 2 diabetes can be related to the disease itself or to the treatments used to manage diabetes. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"      \"Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      PREGNANCY AND DIABETES",
"     </span>",
"    </p>",
"    <p>",
"     Women with type 2 diabetes are usually able to become pregnant and have a healthy baby. A full discussion of diabetes in pregnancy is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=see_link\">",
"      \"Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14372652\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/29/28115?source=see_link\">",
"      Patient information: Polycystic ovary syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40179?source=see_link\">",
"      Patient information: Hemochromatosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/14/227?source=see_link\">",
"      Patient information: Hemoglobin A1C tests (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/14/38114?source=see_link\">",
"      Patient information: Nonalcoholic steatohepatitis (NASH) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/47/15091?source=see_link\">",
"      Patient information: Preparing for pregnancy when you have diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/8/40066?source=see_link\">",
"      Patient information: Acromegaly (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/25/15763?source=see_link\">",
"      Patient information: Preventing type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/2/36898?source=see_link\">",
"      Patient information: Diabetic ketoacidosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/6/25699?source=see_link\">",
"      Patient information: Hyperosmolar nonketotic coma (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/52/20292?source=see_link\">",
"      Patient information: Diabetes and infections (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/53/3923?source=see_link\">",
"      Patient information: Health risks of obesity (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14372760\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/60/6083?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Alcohol, exercise, and medical care (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/38/43618?source=see_link\">",
"      Patient information: Foot care in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/63/4083?source=see_link\">",
"      Patient information: Hypoglycemia (low blood sugar) in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?40/1/40980?source=see_link\">",
"      Patient information: Preventing complications in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/32/31239?source=see_link\">",
"      Patient information: Type 2 diabetes mellitus and diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/13/32979?source=see_link\">",
"      Patient information: Gestational diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/37/36436?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/28/18886?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Insulin treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/45/10966?source=see_link\">",
"      Patient information: Care during pregnancy for women with type 1 or 2 diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29641?source=see_link\">",
"      Blood glucose self-monitoring in management of adults with diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=see_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38758?source=see_link\">",
"      Diagnosis of diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20265?source=see_link\">",
"      Effects of exercise in diabetes mellitus in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11993?source=see_link\">",
"      Estimation of blood glucose control in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7578?source=see_link\">",
"      Glycemic control and vascular complications in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30089?source=see_link\">",
"      Insulin therapy in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27641?source=see_link\">",
"      Management of hypoglycemia during treatment of diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/19/28986?source=see_link\">",
"      Management of persistent hyperglycemia in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/2/25641?source=see_link\">",
"      Nutritional considerations in type 1 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/18/14634?source=see_link\">",
"      Nutritional considerations in type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/30/29162?source=see_link\">",
"      Prediction and prevention of type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=see_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/4/5189?source=see_link\">",
"      Smoking and cardiovascular risk in diabetes mellitus",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/42/682?source=see_link\">",
"      Treatment of type 2 diabetes mellitus in the elderly patient",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Diabetes Association (ADA)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(800)-DIABETES (800-342-2383)",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.diabetes.org/\">",
"      www.diabetes.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp; (",
"     <a class=\"external\" href=\"file://www.hormone.org/public/diabetes.cfm\">",
"      www.hormone.org/public/diabetes.cfm",
"     </a>",
"     , available in English and Spanish)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?9/22/9572/abstract/1,2\">",
"      1,2",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 22, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?9/22/9572?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/22/9572/abstract/1\">",
"      Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/22/9572/abstract/2\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f9_22_9572=[""].join("\n");
var outline_f9_22_9572=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           THE IMPACT OF DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           CAUSES OF TYPE 2 DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           TYPE 2 DIABETES DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           TYPE 2 DIABETES TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           TYPE 2 DIABETES COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           PREGNANCY AND DIABETES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/2/12325\" title=\"figure 1\">",
"           Pancreas anatomy",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f9_22_9573="Dapsone (systemic): Patient drug information";
var content_f9_22_9573=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dapsone (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/7/29814?source=see_link\">",
"     see \"Dapsone (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/20/39237?source=see_link\">",
"     see \"Dapsone (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat infections caused by",
"       <i>",
"        Pneumocystis jirovecii",
"       </i>",
"       .",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat bacterial infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691810",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat a skin problem called dermatitis herpetiformis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691927",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leprosy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692151",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may be used to stop or treat toxoplasmosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691520",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat malaria.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dapsone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697168",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have anemia, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697879",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Allergic side effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11647 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-76D4E16EBB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_22_9573=[""].join("\n");
var outline_f9_22_9573=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027095\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027094\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027099\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027100\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027102\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027097\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027098\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027103\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027104\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/7/29814?source=related_link\">",
"      Dapsone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/20/39237?source=related_link\">",
"      Dapsone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/34/44579?source=related_link\">",
"      Dapsone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/51/1844?source=related_link\">",
"      Dapsone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/40/10883?source=related_link\">",
"      Dapsone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_22_9574="Goserelin: Drug information";
var content_f9_22_9574=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Goserelin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?27/0/27652?source=see_link\">",
"    see \"Goserelin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F177201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zoladex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F177202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zoladex&reg;;",
"     </li>",
"     <li>",
"      Zoladex&reg; LA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F177239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Gonadotropin-Releasing Hormone Agonist;",
"     </li>",
"     <li>",
"      Gonadotropin Releasing Hormone Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F177204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prostate cancer, advanced:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      28-day implant:",
"     </i>",
"     3.6 mg every 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      12-week implant:",
"     </i>",
"     10.8 mg every 12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prostate cancer, locally confined (in combination with an antiandrogen and radiotherapy; begin 8 weeks prior to radiotherapy):",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Combination 28-day/12-week implant:",
"     </i>",
"     3.6 mg implant, followed in 28 days by 10.8 mg implant",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      28-day implant (alternate dosing):",
"     </i>",
"     3.6 mg; repeated every 28 days for a total of 4 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer, advanced:",
"     </b>",
"     SubQ: 3.6 mg every 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Endometriosis:",
"     </b>",
"     SubQ: 3.6 mg every 28 days for 6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Endometrial thinning:",
"     </b>",
"     SubQ: 3.6 mg every 28 days for 1 or 2 doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F177205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9404806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment is necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9404807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No adjustment is necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F177180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Implant, subcutaneous:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zoladex&reg;: 3.6 mg (1s) [1 month implant]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zoladex&reg;: 10.8 mg (1s) [3 month implant]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F177166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F177183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Administer implant by inserting needle at a 30-45 degree angle into the anterior abdominal wall below the navel line. Goserelin is an implant; therefore, do not attempt to eliminate air bubbles prior to injection (may displace implant). Do not attempt to aspirate prior to injection; if a large vessel is penetrated, blood will be visualized in the syringe chamber (if vessel is penetrated, withdraw needle and inject elsewhere with a new syringe). Do not penetrate into muscle or peritoneum. Implant may be detected by ultrasound if removal is required.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F177181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of locally confined prostate cancer; palliative treatment of advanced prostate cancer; palliative treatment of advanced breast cancer in pre- and perimenopausal women; treatment of endometriosis, including pain relief and reduction of endometriotic lesions; endometrial thinning agent as part of treatment for dysfunctional uterine bleeding",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F177237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages reported with the 1-month implant:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (female 21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (female 32% to 75%; male 1% to 5%), emotional lability (female 60%), depression (female 54%; male 1% to 5%), pain (female 17%; male 8%), insomnia (female 11%; male 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne (female 42%), seborrhea (female 26%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hot flashes (female 57% to 96%; male 62%), libido decreased (female 48% to 61%), sexual dysfunction (male 21%), breast atrophy (female 33%), breast enlargement (female 18%), erections decreased (18%), libido increased (female 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (female 8% to 11%; male 5%), abdominal pain (female 7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginitis (75%), pelvic symptoms (female 9% to 18%), dyspareunia (female 14%), lower urinary symptoms (male 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bone mineral density decreased (female 23%; ~4% decrease from baseline in 6 months; postmarketing reports in males), weakness (female 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (female 16% to 45%; male 6%), tumor flare (female: 23%), infection (female 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, chest pain, cerebrovascular accident, edema, heart failure, hypertension, MI, palpitation, peripheral vascular disorder, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Abnormal thinking, anxiety, chills, dizziness, fever, lethargy, malaise, migraine, nervousness, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia, bruising, dry skin, hair disorder, hirsutism, pruritus, rash, skin discoloration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast pain, breast swelling/tenderness, dysmenorrhea, gout, hyperglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, appetite increased, constipation, diarrhea, dyspepsia, flatulence, ulcer, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary frequency, urinary obstruction, urinary tract infection, vaginal hemorrhage, vulvovaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Application site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain , hypertonia, joint disorder, leg cramps, myalgia, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Amblyopia, dry eyes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal insufficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis, COPD, cough, epistaxis, pharyngitis, rhinitis, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, flu-like syndrome, voice alteration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): ALT increased, anaphylaxis, AST increased, diabetes, glucose tolerance decreased, hypercalcemia, hypercholesterolemia, hyperlipidemia, hypersensitivity reactions, hypotension, ovarian cyst, pituitary apoplexy, psychotic disorders, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F177186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to goserelin, GnRH, GnRH agonist analogues, or any component of the formulation; pregnancy (except if using for palliative treatment of advanced breast cancer)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F177170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cervical resistance: Cervical resistance may be increased; use caution when dilating the cervix.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Decreased bone density: Has been reported in women and may be irreversible; use caution if other risk factors are present; evaluate and institute preventative treatment if necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercalcemia: Has been reported in prostate and breast cancer patients with bone metastases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperglycemia: Hyperglycemia has been reported in males and may manifest as diabetes or worsening of pre-existing diabetes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Allergic hypersensitivity reactions (including anaphylaxis) and antibody formation may occur; monitor.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pituitary apoplexy: Rare cases of pituitary apoplexy (frequently secondary to pituitary adenoma) have been observed with GnRH agonist administration (onset from 1 hour to usually &lt;2 weeks); may present as sudden headache, vomiting, visual or mental status changes, and infrequently cardiovascular collapse; immediate medical attention required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Spinal cord compression: Has been reported when used for prostate cancer; closely observe patients for weakness and paresthesias in first few weeks of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor flare: Transient increases in serum testosterone (in men with prostate cancer) and estrogen (in women with breast cancer) may result in a worsening of disease signs and symptoms (tumor flare) during the first few weeks of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Urinary tract obstruction: Has been reported when used for prostate cancer; closely observe patients for urinary tract obstruction in first few weeks of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Androgen-deprivation therapy may increase the risk for cardiovascular disease (Levine, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Obese patients: A decreased AUC may be observed when using the 3-month implant in obese patients. Monitor testosterone levels if desired clinical response is not observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Women: Women of childbearing potential should not receive therapy until pregnancy has been excluded. Nonhormonal contraception is recommended during therapy and for 12 weeks after therapy is discontinued. The 3-month implant currently has no approved indications for use in women",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F177177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (endometriosis, endometrial thinning); D (advanced breast cancer) (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F177189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Goserelin has been found to be teratogenic and increases pregnancy loss in animal studies. Goserelin induces hormonal changes which increase the risk for fetal loss and use is contraindicated in pregnancy unless being used for palliative treatment of advanced breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Breast cancer: If used for the palliative treatment of breast cancer during pregnancy, the potential for increased fetal loss should be discussed with the patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endometriosis, endometrial thinning: Women of childbearing potential should not receive therapy until pregnancy has been excluded. Nonhormonal contraception is recommended for premenopausal women during therapy and for 12 weeks after therapy is discontinued. Although ovulation is usually inhibited and menstruation may stop, pregnancy prevention is not ensured during goserelin therapy. Changes in reproductive function may occur following chronic administration.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F177209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9404689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Goserelin is inactivated when used orally. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F177188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Implant",
"     </b>",
"     (Zoladex Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.6 mg (1): $451.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10.8 mg (1): $1353.58",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9404926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bone mineral density, serum calcium, cholesterol/lipids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostate cancer: Weakness, paresthesias, and urinary tract obstruction in first few weeks of therapy; screen for diabetes",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F177190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Zoladex (AE, AR, AT, BB, BD, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HU, ID, IE, IL, IN, IQ, IR, IT, JM, JO, JP, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, NO, OM, PA, PE, PH, PK, PL, PR, PT, QA, RU, SA, SC, SD, SE, SG, SK, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UG, UY, VE, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Zoladex Depot (KP);",
"     </li>",
"     <li>",
"      Zoladex Implant (AT, AU, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, NO, PL, PT, RU, SE, SK, TR);",
"     </li>",
"     <li>",
"      Zoladex Inj. (NZ);",
"     </li>",
"     <li>",
"      Zoladex LA (AR, BB, BM, BR, BS, CO, ID, IL, IN, JM, MY, NL, PE, PH, PR, SG, TH, TT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F177169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Goserelin (a gonadotropin-releasing hormone [GnRH] analog) causes  an initial increase in luteinizing hormone (LH) and follicle stimulating hormone (FSH), chronic administration of goserelin results in a sustained suppression of pituitary gonadotropins. Serum testosterone falls to levels comparable to surgical castration. The exact mechanism of this effect is unknown, but may be related to changes in the control of LH or down-regulation of LH receptors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F177185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: Estradiol suppression reaches postmenopausal levels within 3 weeks and FSH and LH are suppressed to follicular phase levels within 4 weeks of initiation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Males: Testosterone suppression reaches castrate levels within 2-4 weeks after initiation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Females: Estradiol, LH and FSH generally return to baseline levels within 12 weeks following the last monthly implant.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Males: Testosterone levels maintained at castrate levels throughout the duration of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: SubQ: Rapid and can be detected in serum in 30-60 minutes; 3.6 mg: released slowly in first 8 days, then rapid and continuous release for 28 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Male: 44.1 L; Female: 20.3 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 27%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: SubQ: Male: 12-15 days, Female: 8-22 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: SubQ: Male: ~4 hours, Female: ~2 hours; Renal impairment: Male: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&gt;90%; 20% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Ahmann FR, Citrin DL, deHaan HA, et al, &ldquo;Zoladex: A Sustained-Release, Monthly Luteinizing Hormone-Releasing Hormone Analog for the Treatment of Advanced Prostate Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1987, 5(6):912-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9574/abstract-text/2953870/pubmed\" id=\"2953870\" target=\"_blank\">",
"        2953870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baum M, Hackshaw A, Houghton J, et al, &ldquo;Adjuvant Goserelin in Pre-Menopausal Patients With Early Breast Cancer: Results From the ZIPP Study,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2006, 42(7):895-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9574/abstract-text/16545560/pubmed\" id=\"16545560\" target=\"_blank\">",
"        16545560",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brogden RN and Faulds D, &ldquo;Goserelin. A Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy in Prostate Cancer,&rdquo;",
"      <i>",
"       Drugs Aging",
"      </i>",
"      , 1995, 6(4);324-43.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gnant M,  Mlineritsch B, Stoeger  H, et al, &ldquo;Mature Results From ABCSG-12: Adjuvant Ovarian Suppression Combined With Tamoxifen or Anastrozole, Alone or in Combination With Zoledronic Acid, in Premenopausal Women With Endocrine-Responsive Early Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 28(15s):533 [abstract 533 from 2008 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldspiel BR and Kohler DR, &ldquo;Goserelin Acetate Implant: A Depot Luteinizing Hormone-Releasing Hormone Analog for Advanced Prostate Cancer,&rdquo;",
"      <i>",
"       DICP",
"      </i>",
"      , 1991, 25(7-8):796-804.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9574/abstract-text/1835221/pubmed\" id=\"1835221\" target=\"_blank\">",
"        1835221",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hackshaw A, Baum M, Fornander T, et al, &ldquo;Long-Term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2009, 101(5):341-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9574/abstract-text/19244174/pubmed\" id=\"19244174\" target=\"_blank\">",
"        19244174",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Horwitz EM, Bae K, Hanks GE, et al, &ldquo;Ten-Year Follow-Up of Radiation Therapy Oncology Group Protocol 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(15):2497-504.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9574/abstract-text/18413638/pubmed\" id=\"18413638\" target=\"_blank\">",
"        18413638",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, D&rsquo;Amico AV, Berger P, et al, &ldquo;Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk. A Science Advisory from the American Heart Association, American Cancer Society, and American Urological Association,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 121(6):833-40",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9574/abstract-text/20124128/pubmed\" id=\"20124128\" target=\"_blank\">",
"        20124128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Prostate Cancer,&rdquo; Version 3.2010. Available at file://www.nccn.org/professionals/physician_gls/PDF/prostate.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roach M 3rd, Bae K, Speight J, et al, &ldquo;Short-Term Neoadjuvant Androgen Deprivation Therapy and External-Beam Radiotherapy for Locally Advanced Prostate Cancer: Long-Term Results of RTOG 8610,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(4):585-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9574/abstract-text/18172188/pubmed\" id=\"18172188\" target=\"_blank\">",
"        18172188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8500 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A18C3F2596-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_22_9574=[""].join("\n");
var outline_f9_22_9574=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177201\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177202\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177239\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177204\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177205\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9404806\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9404807\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177180\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177166\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177183\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177181\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177237\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177186\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177170\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299420\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220698\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177177\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177189\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177209\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9404689\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177188\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9404926\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177190\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177169\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177185\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8500\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8500|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?27/0/27652?source=related_link\">",
"      Goserelin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_22_9575="Antihemophilic factor/von Willebrand factor complex (human): Pediatric drug information";
var content_f9_22_9575=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Antihemophilic factor/von Willebrand factor complex (human): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/0/39942?source=see_link\">",
"    see \"Antihemophilic factor/von Willebrand factor complex (human): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?22/51/23348?source=see_link\">",
"    see \"Antihemophilic factor/von Willebrand factor complex (human): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3000299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alphanate&reg; ;",
"     </li>",
"     <li>",
"      Humate-P&reg;;",
"     </li>",
"     <li>",
"      Wilate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Humate-P&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3958727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihemophilic Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Blood Product Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F3958736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/0/39942?source=see_link\">",
"      see \"Antihemophilic factor/von Willebrand factor complex (human): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Individualize dosage based on coagulation studies performed prior to and during treatment at regular intervals:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hemophilia A; Factor VIII deficiency:",
"     </b>",
"     Alphanate&reg;, Humate-P&reg;: General guidelines provided (consult specific product labeling for Alphanate&reg; or Humate-P&reg;):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants, Children, Adolescents, and Adults: Limited data in pediatric patients &lt;16 years: I.V.:  In general, administration of 1 international unit/kg of factor VIII will increase circulating factor VIII levels by ~2 units/dL (or 2%); calculated dosage should be adjusted to the actual vial size.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     The formula to calculate required dosage based on desired increase in factor VIII (% of normal);",
"     <b>",
"      Note:",
"     </b>",
"     This formula assumes that the patient&rsquo;s baseline AHF level is &lt;1%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     International units required = Body weight (kg) x 0.5 x desired increase in factor VIII (international units or % of normal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Minor hemorrhage: Loading dose: FVIII:C 15 international units/kg to achieve FVIII:C plasma level ~30% of normal. One infusion may be adequate. If second infusion is needed, half the loading dose may be given once or twice daily for 1-2 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Moderate hemorrhage: Loading dose: FVIII:C 25 international units/kg to achieve FVIII:C plasma level ~50% of normal. Maintenance: FVIII:C 15 international units/kg every 8-12 hours for 1-2 days in order to maintain FVIII:C plasma levels at 30% of normal. Repeat the same dose once or twice daily for up to 7 days or until adequate wound healing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Life-threatening hemorrhage: Loading dose: FVIII:C 40-50 international units/kg. Maintenance: FVIII:C 20-25 international units/kg every 8 hours to maintain FVIII:C plasma levels at 80% to 100% of normal for 7 days. Continue same dose once or twice daily for another 7 days in order to maintain FVIII:C levels at 30% to 50% of normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      von Willebrand disease (VWD); treatment: Dosage is expressed in international units of von Willebrand factor: Ristocetin cofactor (VWF:RCo):",
"     </b>",
"     Dose must be individualized based on type of VWD, extent and location of bleeding, clinical status of patient, and coagulation studies performed prior to and at regular intervals during treatment. Products are not identical and should not be used interchangeably (NHLBI, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hemorrhage:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Humate P:",
"     </b>",
"     Infants, Children, Adolescents, and Adults: I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     In general, administration of 1 international unit/kg of factor VIII would be expected to raise circulating VWF:RCo ~5 units/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Type 1, mild VWD: Major hemorrhage or minor hemorrhage (if desmopressin is not appropriate):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Loading dose: 40-60 international units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Maintenance dose: 40-50 international units/kg/dose every 8-12 hours for 3 days, maintain VWF:RCo nadir  &gt;50%; follow with 40-50 international units/kg once daily for up to 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Type 1, moderate or severe VWD:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Minor hemorrhage: 40-50 international units/kg/dose for 1-2 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Major hemorrhage:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Loading dose: 50-75 international units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Maintenance dose: 40-60 international units/kg/dose every 8-12 hours for 3 days; maintain VWF:RCo nadir &gt;50%; follow with 40-60 international units/kg/dose once daily for up to 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     <i>",
"      Types 2  and 3 VWD:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Minor hemorrhage: 40-50 international units/kg/dose for 1-2 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Major hemorrhage:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Loading dose: 60-80 international units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Maintenance dose: 40-60 international units/kg/dose every 8-12 hours for 3 days, maintain VWF:RCo nadir &gt;50%; follow with 40-60 international units/kg/dose once daily for up to 7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Wilate:",
"     </b>",
"     Children &ge;5 years,  Adolescents, and Adults: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Minor hemorrhage:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Loading dose: 20-40 international units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Maintenance dose: 20-30 international units/kg/dose every 12-24 hours for &le;3 days, keeping the VWF:RCo nadir &gt;30%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Major hemorrhage:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Loading dose: 40-60 international units/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Maintenance dose: 20-40 international units/kg/dose every 12-24 hours for 5-7 days, keeping the VWF:RCo nadir &gt;50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      von Willebrand disease (VWD); surgical/procedural prophylaxis: Note:",
"     </b>",
"     Not for patients with type 3 VWD undergoing major surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Alphanate:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants, Children, and Adolescents: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Preoperative dose: 75 international units/kg as a single dose 1 hour prior to surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Maintenance dose: 50-75 international units/kg/dose every 8-12 hours as clinically needed. May reduce dose after third postoperative day; continue treatment until healing is complete. Goal is to keep the VWF:RCo nadir &gt; 50 international units/dL at least for the first 3 days (NHLBI, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults (except patients with type 3 undergoing major surgery): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Preoperative dose: 60 international units/kg 1 hour prior to surgery",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Maintenance dose: 40-60 international units/kg/dose every 8-12 hours as clinically needed. May reduce dose after third postoperative day; continue treatment until healing is complete. For minor procedures, maintain VWF of 40% to 50% during postoperative days 1-3; for major procedures maintain VWF of 40% to 50% for &ge;3-7 days postoperative.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Humate-P&reg;:",
"     </b>",
"     Infants, Children, Adolescents, and Adults: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Emergency surgery: 50-60 international units/kg; monitor trough coagulation factor levels for subsequent doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Surgical management (nonemergency):",
"     <b>",
"      Note:",
"     </b>",
"     Whenever possible, the",
"     <i>",
"      in vivo",
"     </i>",
"     recovery (IVR) should be measured and baseline plasma VWF:RCo and FVIII activity should be assessed in all patients prior to surgery. The formula to calculate the IVR is as follows: Measure baseline plasma VWF:RCo; then infuse VWF:RCo 60 international units/kg I.V. at time zero; measure VWF:RCo at 30 minutes after infusion. IVR = (plasma VWF:RCo at 30 minutes minus plasma VWF:RCof at baseline) divided by 60 international units/kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Loading dose: Loading dose calculation based on baseline target VWF:RCo: (Target peak VWF:RCo - Baseline VWF:RCo) x weight (in kg) / IVR = international units VWF:RCo required. Administer loading dose 1-2 hours prior to surgery.",
"     <b>",
"      Note:",
"     </b>",
"     If",
"     <i>",
"      in vivo",
"     </i>",
"     recovery (IVR) is not available, assume IVR of 2 international units/dL for every one VWF:RCo international unit/kg administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Target peak VWF:RCo concentrations following loading dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Major surgery/emergency: 100 international units/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Minor/oral surgery: 50-60 international units/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Oral surgery is &lt;2 extractions of nonmolars without bony involvement; extractions of &ge;2 teeth or &gt;1 impacted wisdom tooth is considered major surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Maintenance dose: Initial: One-half loading dose followed by subsequent dosing determined by target trough concentrations, generally administered every 8-12 hours; patients with shorter half-lives may require dosing every 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Target maintenance trough VWF:RCo concentrations and minimum duration of treatment:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Major surgery: &gt;50 international units/dL for up to 3 days, followed by &gt;30 international units/dL; minimum duration of treatment: 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Minor surgery: &ge;30 international units/dL; minimum duration  of  treatment: 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:12em;\">",
"     Oral surgery: &ge;30 international units/dL; minimum duration of treatment:  8-12 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3000423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [human derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alphanate&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     250 units [Factor VIII and VWF:RCo ratio varies by lot; contains sodium &ge;10 mEq/vial, albumin and polysorbate 80; packaged with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     500 units [Factor VIII and VWF:RCo ratio varies by lot; contains sodium &ge;10 mEq/vial, albumin and polysorbate 80; packaged with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1000 units [Factor VIII and VWF:RCo ratio varies by lot; contains sodium &ge;10 mEq/vial, albumin and polysorbate 80; packaged with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1500 units [Factor VIII and VWF:RCo ratio varies by lot; contains sodium &ge;10 mEq/vial, albumin and polysorbate 80; packaged with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Humate-P&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FVIII 250 units and VWF:RCo 600 units [contains albumin; packaged with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FVIII 500 units and VWF:RCo 1200 units [contains albumin; packaged with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FVIII 1000 units and VWF:RCo 2400 units [contains albumin; packaged with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Wilate&reg;:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FVIII 450 units and VWF:RCo 450 units [contains polysorbate 80 (in diluent); packaged with diluent] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FVIII 500 units and VWF:RCo 500 units [contains polysorbate 80 (in diluent); packaged with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FVIII 900 units and VWF:RCo 900 units [contains polysorbate 80 (in diluent); packaged with diluent] [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     FVIII 1000 units and VWF:RCo 1000 units [contains polysorbate 80 (in diluent); packaged with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3000444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3958737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reconstitution: If refrigerated, the dried concentrate and diluent should be warmed to room temperature before reconstitution; see product labeling for specific reconstitution guidelines; gently swirl or rotate vial after adding diluent, do not shake vigorously. Use provided filter transfer set to withdraw solution from vial of Alphanate&reg; or Humate-P&reg;; remove filter spike prior to administration. Use provided transfer device to reconstitute Wilate&reg;.",
"     <b>",
"      Note:",
"     </b>",
"     Use plastic syringes;  AHF may stick to the surface of glass syringes. Discard unused contents and administration equipment after use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: I.V.: Administer through a separate line, do not mix with drugs or other I.V. fluids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Alphanate&reg;: Infuse slowly; maximum rate: 10 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Humate-P&reg;: Infuse slowly; maximum rate: 4 mL/minute",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Wilate&reg;: Infuse slowly at a rate of 2-4 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F3958733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Alphanate&reg;: Store intact vials at &le;25&deg;C (77&deg;F); do not freeze. Use within 3 hours of reconstitution; do not refrigerate after reconstitution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Humate-P&reg;: Store intact vials at &le;25&deg;C (&le;77&deg;F); avoid freezing. Use within 3 hours of reconstitution. Do not refrigerate after reconstitution, precipitation may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Wilate&reg;: Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Protect from light. Intact vials may also be stored at room temperature [not to exceed 25&deg;C (77&deg;F)] for &le;6 months. Once stored at room temperature, do not return to the refrigerator. Following reconstitution, use solution immediately.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3958728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemophilia A (Factor VIII deficiency): Alphanate&reg;, Humate-P&reg;: Prevention and treatment of hemorrhagic episodes in hemophilia A (classic hemophilia) (Alphanate&reg;: FDA approved in ages &gt;16 years and adults; Humate-P&reg;: FDA approved in adults); prevention and treatment of hemorrhagic episodes with acquired factor VIII deficiency (Alphanate&reg;: FDA approved in ages &gt;16 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     von Willebrand disease (VWD):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Alphanate&reg;: Prophylaxis for surgical and/or invasive procedures in patients with VWD when desmopressin is either ineffective or contraindicated [FDA approved in pediatric patients (age not specified) and adults].",
"     <b>",
"      Note:",
"     </b>",
"     Not indicated for patients with severe VWD undergoing major surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Humante-P&reg;: Treatment of spontaneous and trauma-induced hemorrhagic episodes and prevention of excessive perioperative bleeding in patients with mild to moderate and severe VWD where the use of desmopressin is suspected or known to be inadequate (FDA approved in ages &ge;1 month and adults).",
"     <b>",
"      Note:",
"     </b>",
"     Not indicated for the prophylaxis of spontaneous bleeding episodes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Wilate&reg;: Treatment of spontaneous and trauma-induced bleeding in patients with severe VWD, including mild or moderate disease when use of desmopressin is known or suspected to be inadequate or contraindicated (FDA approved in  ages &ge;5 years and adults).",
"     <b>",
"      Note:",
"     </b>",
"     Not indicated for prophylaxis of spontaneous bleeding or prevention of excessive bleeding during and after surgery.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11595830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Factor VIII may be confused with Factor XIII",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F3000356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiorespiratory arrest, chest tightness, edema, femoral venous thrombosis, flushing, hypervolemia, orthostatic hypotension, shock, thromboembolic events, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, dizziness, fever, headache, lethargy, pain, seizure, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Itching, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Parotid gland swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Hematocrit decreased (moderate), hemorrhage, hemolysis, pseudothrombocytopenia (severe)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site stinging, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Extremity pain, joint pain, paresthesia, rigors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pharyngitis, pulmonary embolus (large doses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylactic reactions, factor VIII inhibitor formation, hypersensitivity reactions, von Willebrand factor inhibitor formation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3958730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of anaphylactic or severe systemic response to antihemophilic factor (AHF) or von Willebrand factor products; hypersensitivity to any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F4028795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Human antihemophilic factor/von Willebrand factor complex is prepared from pooled plasma; even with heat treated or other viral attenuated processes, the risk of viral transmission (ie, viral hepatitis, HIV, parvovirus B19, and theoretically, Creutzfeldt-Jakob disease agent) is not totally eradicated. Hepatitis B vaccination is recommended for all patients receiving human antihemophilic factor/von Willebrand factor complex  and hepatitis A vaccination is recommended for seronegative patients.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Alphanate&reg;, Humate-P&reg; contain trace amounts of blood groups A and B isohemagglutinins; progressive anemia and hemolysis may occur in individuals with blood groups A, B, and AB who receive large or frequent doses of human antihemophilic factor/von Willebrand factor complex due to trace amounts of blood group A and B isohemagglutinins; use with caution in these patients.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Formation of factor VIII inhibitors (neutralizing antibodies to AHF human) may occur, particularly in patients with Type 3 (severe) von Willebrand factor; reported overall incidence is 3% to 52%; an increase of inhibitor antibody concentration is seen at 2-7 days, with peak concentrations at 1-3 weeks after therapy; children &lt;5 years of age may also be at greatest risk. Patients who develop antibodies (usually antibody concentration &gt;10 Bethesda units/mL) against von Willebrand factor will not have an effective clinical response to therapy and infusions may result in anaphylactic reactions; these patients should be managed by an experienced physician and alternatives to therapy should be considered. Any patient who has an inadequate response to therapy or a severe adverse reaction should be evaluated for the presence of inhibitors. The dosage requirement will vary in patients with factor VIII inhibitors; optimal treatment should be determined by clinical response. In patients with Hemophilia A, the dosage requirement will vary in patients with factor VIII inhibitors; optimal treatment should be determined by clinical response.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F4808679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Thromboembolic events in patients with von Willebrand disease receiving antihemophilic factor/von Willebrand factor complex have been reported; risk of these events may be increased with ongoing use; monitor concentrations of von Willebrand factor and factor VIII closely; avoid excessive increases in factor VIII activity. Incidence of thrombosis may be increased in patients with other risk factors for thrombosis and females. Allergic reactions, including anaphylaxis, has been observed; monitor patients closely during infusion; patients experiencing anaphylactic reactions should be evaluated for the presence of inhibitors; discontinue therapy immediately if urticaria, hives, hypotension, tightness of the chest, wheezing, dyspnea, faintness, or anaphylaxis develop.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Alphanate&reg; and Wilate&reg; contain polysorbate 80 (Tween 80&reg;) which may cause allergic reactions in susceptible individuals. In premature neonates, thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). Infusion of polysorbate 80-containing solutions through polyvinyl chloride tubing may cause DEHP to leach into the solution; in immature animals, exposure to DEHP may adversely affect the development of the male reproductive tract.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6218025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3000346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3000347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Safety and efficacy in pregnant women have not been established. Use during pregnancy only if clearly needed. Parvovirus B19 or hepatitis A, which may be present in plasma-derived products, may affect a pregnant woman more seriously than nonpregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3958738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of intravascular hemolysis or bleeding; heart rate and blood pressure (before and during I.V. administration). AHF levels prior to and during treatment; in patients with circulating inhibitors, the inhibitor level should be monitored; hematocrit; VWF activity (circulating levels of functional VWF are measured as ristocetin cofactor activity [VWF:RCo]). In surgical patients, monitor VWF:RCo at baseline and after surgery, trough VWF:RCo and FVIII:C at least daily.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F3958739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hemophilia: Classification of hemophilia; normal is defined as 1 unit/mL of factor VIII:C",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe: Factor level &lt;1% of normal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moderate: Factor level 1% to 5% of normal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild: Factor level &gt;5% to 30% of normal",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3958734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Factor VIII and von Willebrand factor (VWF), obtained from pooled human plasma, are used to replace endogenous factor VIII and VWF in patients with hemophilia or VWD. Factor VIII is a protein in normal plasma which is necessary for clot formation and maintenance of hemostasis; it activates factor X in conjunction with activated factor IX; activated factor X converts prothrombin to thrombin, which converts fibrinogen to fibrin and with factor XIII forms a stable clot. VWF promotes platelet aggregation and adhesion to damaged vascular endothelium and acts as a stabilizing carrier protein for factor VIII. [Circulating levels of functional VWF are measured as ristocetin cofactor activity (VWF:RCo)]",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F4028796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: Shortening of bleeding time: Immediate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: VWD: Shortening of bleeding time: &lt;6 hours postinfusion; VWF multimers detected in the plasma: 24 hours after infusion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3958735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : VWF:RCo: 53-72 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     FVIII coagulant activity (FVIIIC 8-28 hours in patients with hemophilia A",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     VWF:RCo: 3-34 hours in patients with VWD",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F3958740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/51/23348?source=see_link\">",
"      see \"Antihemophilic factor/von Willebrand factor complex (human): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     This medication can only be given intravenously. Notify physician immediately if any of the following signs or symptoms of an allergic (hypersensitivity) reaction occur: Itching, hives, low blood pressure, tightness in chest, wheezing, or anaphylaxis. Report immediately any sudden-onset headache, chest or back pain, low-grade fever, stomach pain, or nausea/vomiting to prescriber. Wear identification indicating a hemophilic condition.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F4028798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     One international unit of AHF is equal to the factor VIII activity present in 1 mL of normal human plasma. If bleeding is not controlled with adequate dose, test for the presence of factor VIII inhibitor; larger doses of AHF may be therapeutic with inhibitor titers &lt;10 Bethesda units/mL; it may not be possible or practical to control bleeding if inhibitor titers &gt;10 Bethesda units/mL (due to the very large AHF doses required); other treatments [eg, antihemophilic factor (porcine), factor IX complex concentrates, recombinant factor VIIa, or anti-inhibitor coagulant complex] may be needed in patients with inhibitor titers &gt;10 Bethesda units/mL.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Exact potency varies among products and between lots of the same product; each vial contains the exact labeled amount of VWF activity, as measured with the Ristocetin cofactor activity (VWF:RCo), and factor VIII (FVIII) activity and should be consulted prior to use. However, the average ratio between VWF:RCo and FVIII among available products is:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     Alphanate&reg;: Average ratio not provided by manufacturer or in available literature",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     Humate-P&reg;: Average ratio of VWF:RCo to FVIII is 2.4:1",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;margin-top:0em;\">",
"     Wilate&reg;: Average ratio of VWF:RCo to FVIII is ~1:1",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alade SL, Brown RE, and Paquet A Jr, \"Polysorbate 80 and E-Ferol Toxicity,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1986, 77(4):593-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9575/abstract-text/3960626/pubmed\" id=\"3960626\" target=\"_blank\">",
"        3960626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control (CDC), \"Unusual Syndrome With Fatalities Among Premature Infants: Association With a New Intravenous Vitamin E Product,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 1984, 33(14):198-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9575/abstract-text/6423951/pubmed\" id=\"6423951\" target=\"_blank\">",
"        6423951",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NHLBI VWD Expert Panel, \"The Diagnosis, Evaluation, and Management of von Willebrand Disease. US Department of Health and Human Services, National Institutes of Health, National Heart Lung and Blood Institute, 2007, NIH No. 08-5832.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Federation of Hemophilia, \"Guidelines for the Management of Hemophilia,\" 2005. Available at file://www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Guidelines_Mng_Hemophilia.pdf",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13397 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-118.97.94.19-8B28454533-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_22_9575=[""].join("\n");
var outline_f9_22_9575=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000299\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663155\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3958727\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3958736\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000423\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000444\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3958737\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3958733\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3958728\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11595830\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000356\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3958730\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4028795\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4808679\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298759\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6218025\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000346\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3000347\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3958738\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3958739\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3958734\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4028796\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3958735\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3958740\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4028798\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13397\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13397|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/0/39942?source=related_link\">",
"      Antihemophilic factor/von Willebrand factor complex (human): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?22/51/23348?source=related_link\">",
"      Antihemophilic factor/von Willebrand factor complex (human): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_22_9576="Cyproterone and ethinyl estradiol: Drug information";
var content_f9_22_9576=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyproterone and ethinyl estradiol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/55/9078?source=see_link\">",
"    see \"Cyproterone and ethinyl estradiol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F155844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cyestra-35;",
"     </li>",
"     <li>",
"      Diane-35&reg;;",
"     </li>",
"     <li>",
"      Novo-Cyproterone/Ethinyl Estradiol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F155861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Acne Products;",
"     </li>",
"     <li>",
"      Estrogen and Progestin Combination",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F155847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females: Acne: Oral: One tablet daily for 21 days, followed by 7 days off; first cycle should begin on the first day of menstrual flow. Subsequent dosing cycles should begin on the same day of the week that the first cycle was begun regardless of presence of withdrawal bleeding. Discontinue therapy 3-4 cycles after symptoms have resolved.",
"     <b>",
"      Note:",
"     </b>",
"     Retreatment may be considered with recurrence of symptoms following therapy discontinuation.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F155848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Specific guidelines not available; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F155849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contraindicated in hepatic impairment or active liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Diane-35: Cyproterone 2 mg and ethinyl estradiol 0.035 mg (21s)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11218427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F155829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at the same time each day. Swallow tablet whole. A missed dose may be taken within the next 12 hours. If &gt;12 hours, discard unused tablet and resume at  usual scheduled times.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F155828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of females with severe acne, unresponsive to oral antibiotics and other therapies, with associated symptoms of androgenization (including mild hirsutism or seborrhea).",
"     <b>",
"      Should not be used solely for contraception;",
"     </b>",
"     however, will provide reliable contraception if taken as recommended for approved indications.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F155859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     This listing reflects reactions reported with combination hormonal contraceptives. Percentages specific to this combination are identified in parentheses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Varicosities (3%), edema (2%), arterial thromboembolism, cerebral hemorrhage, cerebral thrombosis, hypertension, mesenteric thrombosis, MI, Raynaud&rsquo;s phenomenon",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache (5%), nervousness (4%), depression (3%), dizziness (1%), migraine, premenstrual syndrome, stroke",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Chloasma (4%), acne, angioedema, erythema multiforme, erythema nodosum, hirsutism, loss of scalp hair, melasma (may persist), rash (allergic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea (10%), breast tenderness (7%), libido changes (3%), amenorrhea, breakthrough bleeding, breast changes (enlargement, secretion), carbohydrate intolerance, lactation decreased (postpartum), menstrual flow changes, spotting, temporary infertility (following discontinuation), thyroid-binding globulin increased, triglycerides increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea (2%), abdominal bloating/cramps, appetite changes, cholestasis, colitis, gallbladder disease, pancreatitis, vomiting, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Cervical erosion changes, cervical secretion changes, cystitis-like syndrome, endocervical hyperplasia, uterine fibroids (leiomyomata) enlarged, vaginal candidiasis, vaginitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Factors VII, VIII, IX, and X increased; folate levels decreased, hemolytic uremic syndrome, porphyria, prothrombin increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, AST increased, benign liver tumors, Budd-Chiari syndrome, cholestatic jaundice, GGT increased, hepatic adenomas, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Thrombophlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Chorea, rheumatoid arthritis exacerbation, synovitis exacerbation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts, change in corneal curvature (steepening), contact lens intolerance, optic neuritis, retinal thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Auditory disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Renal function impaired",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary thromboembolism, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hemorrhagic eruption, systemic lupus erythematosus (SLE)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports (limited to important or life threatening): Abortion, exanthema, focal nodular hyperplasia, hepatic enzymes abnormal,  hepatitis, herpes zoster, hyperprolactinemia, hyperthyroidism, hypoesthesia, missed abortion, myoma, neurodermatitis, ovarian cyst, palpitations, paresthesia, photosensitivity, pigmentation, placental insufficiency, salivary gland swelling, seizures, urinary tract infection, urticaria, vision abnormal",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F155832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ethinyl estradiol, cyproterone, or any component of the formulation; breast cancer or other estrogen- or progestin-dependent neoplasms (current or a history of); hepatic tumors or disease; history of cholestatic jaundice; pregnancy; undiagnosed abnormal vaginal bleeding; ocular lesions arising from ophthalmic vascular disease; history of otosclerosis with deterioration during pregnancy",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use is also contraindicated in women at high risk of arterial or venous thrombotic diseases including: Cerebrovascular disease, coronary artery disease, MI, diabetes mellitus with vascular disease",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F155817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Amenorrhea: Evaluate hypothalamic-pituitary function in women with persistent (&ge;6 months) amenorrhea (especially associated with breast secretion) following discontinuation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angioedema: Estrogens may induce or exacerbate symptoms of angioedema, particularly in women with hereditary angioedema. Discontinuation of therapy may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer: The use of combination hormonal contraceptives has been associated with a slight increase in frequency of breast cancer; however, studies are not consistent. Use is contraindicated in women with breast cancer (current or history of).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carbohydrate intolerance: May have adverse effects on glucose tolerance; use caution in women with diabetes. If patient has diabetes, hypertension, and obesity or if this triad of conditions develops, medication should be discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholestasis: Risk of cholestasis may be increased with previous cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lipid effects: Combination hormonal contraceptives may effect serum triglyceride and lipoprotein levels. Estrogen compounds are generally associated with lipid effects such as increased HDL-cholesterol and decreased LDL-cholesterol. Triglycerides may also be increased; use with caution in patients with familial defects of lipoprotein metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolism:",
"     <b>",
"      [Canadian Boxed Warning]: May increase the risk of thromboembolism;",
"     </b>",
"     discontinue use if an arterial or venous thrombotic event occurs.",
"     <b>",
"      Use is contraindicated in women with a history of thrombophlebitis or thromboembolic disorders. Progesterone and/or estrogen should not be taken while on this medication.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaginal bleeding: Development of irregular, unresolving vaginal bleeding following previously regular cycles warrants further evaluation including endometrial sampling, if indicated, to rule out malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with risk factors for coronary artery disease (eg, hypertension, hypercholesterolemia, morbid obesity, diabetes, or women who smoke); may lead to increased risk of myocardial infarction. May have a dose-related risk of vascular disease and hypertension. Women with androgen-related conditions (severe acne, hirsutism) may have an increased cardiovascular risk. Discontinue use if a significant rise in blood pressure occurs at any time during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, diabetes, or cardiac or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fibroids: Use with caution in patients with fibroids (leiomyomata); discontinue use with sudden enlargement, pain, or tenderness of fibroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gallbladder disease: May have a dose-related risk of gallbladder disease; may worsen existing gallbladder disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic adenomas: Extremely rare adenomas and focal nodular hyperplasia resulting in fatal intra-abdominal hemorrhage have been reported in association with long-term oral contraceptive use. Presentation of an abdominal mass, acute abdominal pain, or intra-abdominal bleeding warrants further evaluation to rule out source.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Combination hormonal contraceptives may be poorly metabolized in women with hepatic impairment. Discontinue if jaundice develops during therapy or if liver function becomes abnormal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Migraine: Use with caution in patients with a history of migraine. Evaluate new, recurrent, severe, or persistent headaches.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular changes: Estrogens may cause retinal vascular thrombosis; discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination. Use with caution in patients with myopia; progressive astigmatic error, possibly leading to keratoconus, has been observed in some myopic women receiving estrogen/progesterone. Women with family history of such disorders may experience rapid advancement of these ocular disorders. Changes in contact lens tolerance or development of visual changes should be evaluated by an ophthalmologist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Not indicated for use after menopause.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for use prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Smokers: [",
"     <b>",
"      Canadian Boxed Warning]: The risk of cardiovascular side effects is increased in women who smoke cigarettes; risk increases with age (especially women &gt;35 years) and the number of cigarettes smoked (&ge;15 cigarettes/day); women who use combination estrogen/progestin therapy should be strongly advised not to smoke.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, drug should be discontinued at least 4 weeks prior to elective surgery; associated with an increased risk of thromboembolism or during periods of prolonged immobilization. Medication should not be restarted until first menstrual period after hospital discharge following surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <b>",
"      [Canadian Boxed Warning]: Should not be prescribed solely for its contraceptive properties.",
"     </b>",
"     Secondary nonhormonal contraception recommended in patients who may not adhere to dosing.",
"     <b>",
"      Should not be used in combination with other estrogen/progestin combination products.",
"     </b>",
"     This combination shares many of the risks of oral contraceptive agents.",
"     <b>",
"      Therapy should be discontinued 3-4 cycles after resolution of symptoms.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory changes: The use of estrogens and/or progestins may change the results of some laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). The dose, route, and the specific estrogen/progestin influences these changes. In addition, personal risk factors (eg, cardiovascular disease, smoking, diabetes, age) also contribute to adverse events; use of specific products may be contraindicated in women with certain risk factors.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F155857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anastrozole: Estrogen Derivatives may diminish the therapeutic effect of Anastrozole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use of a non-hormone-based contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Armodafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with armodafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative (i.e., non-hormonal) means of contraception in all women of childbearing potential who are using artemether.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ascorbic Acid: May increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a non-hormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Contraceptives (Estrogens) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bexarotene (Systemic): May decrease the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential receiving bexarotene should use two reliable forms of contraception (including at least one nonhormonal form).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer estrogen-based oral contraceptives at least 1-4 hours prior to or 4-6 hours after administration of a bile acid sequestrant.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Patients receiving boceprevir, ribavirin, and peginterferon alfa should use two reliable forms of contraception.  Norethindrone/ethinyl estradiol may be used for one of these when norethindrone dose is at least 1 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use an alternative (i.e., non-hormonal) means of contraception for all women of childbearing potential who are using bosentan, and do not rely on hormonal contraceptives alone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Chenodiol: Estrogen Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any estrogen derivative.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloBAZam: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colesevelam: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Estrogen Derivatives may increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: CYP1A2 Inhibitors (Moderate) may decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Substrates: Cyproterone may decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2E1 Substrates: Cyproterone may decrease the serum concentration of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Consider the use of an alternative, non-hormone-based contraceptive, in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Exenatide: May decrease the serum concentration of Contraceptives (Estrogens). Management: Administer oral contraceptives at least one hour prior to exenatide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felbamate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of a nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May decrease the serum concentration of Contraceptives (Estrogens). The active metabolite aprepitant is likely responsible for this effect. Management: Alternative or additional methods of contraception should be used both during treatment with fosaprepitant or aprepitant and for at least one month following the last fosaprepitant/aprepitant dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Griseofulvin: May increase the metabolism of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use an alternative, nonhormonal form of contraception, or use an alternative to griseofulvin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Estrogenic Properties): May enhance the adverse/toxic effect of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HMG-CoA Reductase Inhibitors: Cyproterone may increase the serum concentration of HMG-CoA Reductase Inhibitors.  Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pitavastatin; Pravastatin; Rosuvastatin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Estrogen Derivatives may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving estrogens (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: Contraceptives (Estrogens) may decrease the serum concentration of LamoTRIgine.  Management: Monitor for increased serum concentrations/effects of lamotrigine in patients in whom a hormonal contraceptive is discontinued/dose decreased (this includes during a pill-free week). A reduced dosage of lamotrigine may be needed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Contraceptives (Estrogens). Mifepristone may increase the serum concentration of Contraceptives (Estrogens). Management: Women of childbearing potential should use an effective, nonhormonal means of contraception during and 4 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Modafinil: May decrease the serum concentration of Contraceptives (Estrogens). Management: The manufacturer recommends that patients use nonhormonal contraceptives, in addition to or in place of hormonal contraceptives, during and for one month following treatment with modafinil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: May decrease the serum concentration of Contraceptives (Estrogens). Average AUC values were unchanged, but there was evidence of substantial patient-to-patient variability in response to this combination. Management: Women of childbearing potential who are receiving mycophenolate mofetil should consider using an alternative and/or additional form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Contraceptives (Estrogens). Management: Use of an alternative, nonhormonal form of contraception during nafcillin therapy is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): May enhance the thrombogenic effect of Estrogen Derivatives. NSAID (COX-2 Inhibitor) may increase the serum concentration of Estrogen Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: Estrogen Derivatives may enhance the adverse/toxic effect of Ospemifene. Estrogen Derivatives may diminish the therapeutic effect of Ospemifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal means of contraception is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pirfenidone: CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Pirfenidone.  Management: This combination may be used with caution only if the moderate CYP1A2 inhibitor does not significantly inhibit other CYP enzymes and the patient is not taking any other drugs that do significantly inhibit other specific CYP enzymes.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Contraceptives (Estrogens). Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Indinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: May decrease the serum concentration of Contraceptives (Estrogens).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: May diminish the therapeutic effect of Contraceptives (Estrogens). Two forms of contraception are recommended in females of child-bearing potential during retinoic acid derivative therapy.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Use of an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: Estrogen Derivatives may increase the serum concentration of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rufinamide: May decrease the serum concentration of Ethinyl Estradiol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selegiline: Contraceptives (Estrogens) may increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May diminish the therapeutic effect of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Consider an alternative to St John's wort if possible.  If this combination is used, an alternative, nonhormonal contraceptive is recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May decrease the serum concentration of Contraceptives (Estrogens). Management: Two different nonhormonal forms of contraception are required for women of childbearing potential taking telaprevir.  Hormonal contraceptives may be less effective during concurrent telaprevir and for up to 2 weeks after telaprevir discontinuation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Contraceptives (Estrogens) may increase the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Estrogen Derivatives may diminish the therapeutic effect of Thyroid Products.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: Estrogen Derivatives may enhance the dermatologic adverse effect of Tipranavir. The combination of tipranavir/ritonavir and ethinyl estradiol/norethindrone was associated with a high incidence of skin rash. Tipranavir may decrease the serum concentration of Estrogen Derivatives.  Management: Women using hormonal contraceptives should consider alternative, non-hormonal forms of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TiZANidine: Contraceptives (Estrogens) may increase the serum concentration of TiZANidine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: May decrease the serum concentration of Contraceptives (Estrogens). Contraceptive failure is possible. Management: Risk appears greatest for higher topiramate doses (200 mg/day or greater).  Some have recommended using at least 50 mcg/day of ethinyl estradiol, but the effectiveness of this is unclear.  Consider a nonhormonal form of contraception.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tranexamic Acid: Contraceptives (Estrogens) may enhance the thrombogenic effect of Tranexamic Acid.  Management: Ensure that the potential benefits of concurrent therapy outweigh the increased risk of potential thrombosis that accompanies use of tranexamic acid with hormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ursodiol: Estrogen Derivatives may diminish the therapeutic effect of Ursodiol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Contraceptives (Estrogens) may diminish the anticoagulant effect of Vitamin K Antagonists. In contrast, enhanced anticoagulant effects have also been noted with some products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May decrease the metabolism of Contraceptives (Estrogens). Contraceptives (Estrogens) may increase the serum concentration of Voriconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F155841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: CNS effects of caffeine may be enhanced if combination hormonal contraceptives are used concurrently with caffeine. Grapefruit juice increases ethinyl estradiol concentrations and would be expected to increase progesterone serum levels as well; clinical implications are unclear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels. Herbs with estrogenic properties may enhance the adverse/toxic effect of estrogen derivatives; examples include alfalfa, black cohosh, bloodroot, hops, kudzu, licorice, red clover, saw palmetto, soybean, thyme, wild yam, yucca. Herbs with progestogenic properties may enhance the adverse/toxic effect of progestins; examples include bloodroot, chasteberry, damiana, oregano, yucca.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F155833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pregnancy should be ruled out prior to treatment and discontinued if pregnancy occurs. In general, the use of combination hormonal contraceptives when inadvertently taken early in pregnancy have not been associated with teratogenic effects. Upon discontinuation of therapy, women should use a nonhormonal contraceptive to delay pregnancy until at least one normal cycle has occurred. Due to increased risk of venous thromboembolism (VTE) postpartum, combination hormonal contraceptives should not be started in any woman &lt;21 days following delivery. Women without risk factors for VTE and who are not breast-feeding may start combination hormonal contraceptives during 21-42 days postpartum. After 42 days postpartum, restrictions for use are not related to postpartum status and should be based on other medical conditions (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F155852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13218767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Jaundice and breast enlargement in the nursing infant have been reported following the use of combination hormonal contraceptives. May decrease the quality and quantity of breast milk; alternative form of contraception is recommended (per manufacturer). The theoretical concerns about decreased milk production are greatest early in the postpartum period when milk production is being established. Postpartum risk status for VTE should be considered when initiating combination hormonal contraceptives after delivery. Combined hormonal contraceptives should not be started &lt;21 days postpartum due to increased risk of VTE. Risk of VTE is still elevated in breast-feeding women until ~42 days postpartum and is greater in women with additional risk factors. After 42 days postpartum, restrictions for use are not related to postpartum VTE risk and should be based on other medical conditions (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F155824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Before starting therapy, a physical exam with reference to the breasts and pelvis are recommended, including a Papanicolaou smear. Exam may be deferred if appropriate; pregnancy should be ruled out prior to use. The first follow-up visit should be 3 months after initiation of treatment. Monitor patient closely for loss of vision, sudden onset of proptosis, diplopia, or migraine; blood pressure; signs and symptoms of thromboembolic disorders; signs and symptoms of depression; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias; liver function tests. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F155834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Althea (PH);",
"     </li>",
"     <li>",
"      Ancea (PH);",
"     </li>",
"     <li>",
"      Clairette (KP);",
"     </li>",
"     <li>",
"      Claudia (BE);",
"     </li>",
"     <li>",
"      Climene (DO);",
"     </li>",
"     <li>",
"      Crimson (PH);",
"     </li>",
"     <li>",
"      Cypress (MY, TH);",
"     </li>",
"     <li>",
"      Dafne 35 (TH);",
"     </li>",
"     <li>",
"      Daphne (BE);",
"     </li>",
"     <li>",
"      Diane (AT, BE, EE, FI, IN, MX, NO, RU, SE, TR);",
"     </li>",
"     <li>",
"      Diane 35 (AR, BG, BR, CH, CL, CN, CR, CZ, DE, DK, DO, EC, EE, FR, GT, HK, HN, ID, IL, MY, NI, PA, PE, PH, PK, PY, SG, SV, TH, TW);",
"     </li>",
"     <li>",
"      Diane 35 Diario (ES);",
"     </li>",
"     <li>",
"      Diane-35 (BB, BM, BS, BZ, CO, DO, GY, JM, NL, PR, SR, TT, UY, VE, ZA);",
"     </li>",
"     <li>",
"      Diane-35 ED (AU, NZ);",
"     </li>",
"     <li>",
"      Dianette (IE);",
"     </li>",
"     <li>",
"      Diva-35 (ZA);",
"     </li>",
"     <li>",
"      Dixi-35 (CN, PE, PY);",
"     </li>",
"     <li>",
"      Esdian (TW);",
"     </li>",
"     <li>",
"      Estelle -35 (IL, MY, SG, TW);",
"     </li>",
"     <li>",
"      Estelle-35 ED (AU, ID, NZ);",
"     </li>",
"     <li>",
"      Eunice-35 (MX);",
"     </li>",
"     <li>",
"      Evepar (FR);",
"     </li>",
"     <li>",
"      Facetik (CO);",
"     </li>",
"     <li>",
"      Femina-35 (EE);",
"     </li>",
"     <li>",
"      Feminil (NO);",
"     </li>",
"     <li>",
"      Gynofen 35 (GR);",
"     </li>",
"     <li>",
"      Holgyeme (FR);",
"     </li>",
"     <li>",
"      Juliet-35 ED (AU);",
"     </li>",
"     <li>",
"      Lady-E35 (TH);",
"     </li>",
"     <li>",
"      Lady-Ten 35 (CN);",
"     </li>",
"     <li>",
"      Laila-35 ED (AU);",
"     </li>",
"     <li>",
"      Linface (EC);",
"     </li>",
"     <li>",
"      Minerva-35 (ZA);",
"     </li>",
"     <li>",
"      Nortin (TW);",
"     </li>",
"     <li>",
"      OC-35 (TH);",
"     </li>",
"     <li>",
"      Sucee (MY);",
"     </li>",
"     <li>",
"      Zyrona (SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F155816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethinyl estradiol: Estrogens are responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estrogens modulate the pituitary secretion of gonadotropins, luteinizing hormone, and follicle-stimulating hormone through a negative feedback system. Estrogen increases levels of sex hormone-binding globulin (SHBG) and may reduce unbound androgen levels. Ethinyl estradiol is a synthetic derivative of estradiol. The addition of the ethinyl group prevents rapid degradation by the liver.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cyproterone: Steroidal compound with antiandrogenic, antigonadotropic and progestin-like activity.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F155831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Contraceptive Methods During the Postpartum Period,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(26):878-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9576/abstract-text/21734635/pubmed\" id=\"21734635\" target=\"_blank\">",
"        21734635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sitruk-Ware R and Nath A, \"Metabolic Effects of Contraceptive Steroids,\"",
"      <i>",
"       Rev Endocr Metab Disord",
"      </i>",
"      , 2011, 12(2):63-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9576/abstract-text/21538049/pubmed\" id=\"21538049\" target=\"_blank\">",
"        21538049",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tan J, \"Hormonal Treatment of Acne: Review of Current Best Evidence,\"",
"      <i>",
"       J Cutan Med Surg",
"      </i>",
"      , 2004, 8(Suppl 4):11-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9576/abstract-text/15778821/pubmed\" id=\"15778821\" target=\"_blank\">",
"        15778821",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8579 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C80C007BE0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_22_9576=[""].join("\n");
var outline_f9_22_9576=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155844\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155861\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155847\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155848\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155849\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076210\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11218427\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155829\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155828\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155859\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155832\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155817\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155857\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155821\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155841\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155833\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155852\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13218767\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155824\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155834\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155816\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155831\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8579\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8579|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/55/9078?source=related_link\">",
"      Cyproterone and ethinyl estradiol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_22_9577="Carvedilol: Drug information";
var content_f9_22_9577=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Carvedilol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/15/37109?source=see_link\">",
"    see \"Carvedilol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/63/40952?source=see_link\">",
"    see \"Carvedilol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F146697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Coreg CR&reg;;",
"     </li>",
"     <li>",
"      Coreg&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F146698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Carvedilol&reg;;",
"     </li>",
"     <li>",
"      Ava-Carvedilol;",
"     </li>",
"     <li>",
"      Dom-Carvedilol;",
"     </li>",
"     <li>",
"      JAMP-Carvedilol;",
"     </li>",
"     <li>",
"      Mylan-Carvedilol;",
"     </li>",
"     <li>",
"      Novo-Carvedilol;",
"     </li>",
"     <li>",
"      PMS-Carvedilol;",
"     </li>",
"     <li>",
"      RAN&trade;-Carvedilol;",
"     </li>",
"     <li>",
"      ratio-Carvedilol;",
"     </li>",
"     <li>",
"      ZYM-Carvedilol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F146742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker With Alpha-Blocking Activity",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F146702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce dosage if heart rate drops to &lt;55 beats/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     6.25 mg twice daily; if tolerated, dose should be maintained for 1-2 weeks, then increased to 12.5 mg twice daily. If necessary, dosage may be increased to a maximum of 25 mg twice daily after 1-2 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release:",
"     </i>",
"     Initial: 20 mg once daily, if tolerated, dose should be maintained for 1-2 weeks then increased to 40 mg once daily if necessary; maximum dose: 80 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     3.125 mg twice daily for 2 weeks; if this dose is tolerated, may increase to 6.25 mg twice daily. Double the dose every 2 weeks to the highest dose tolerated by patient. (Prior to initiating therapy, other heart failure medications should be stabilized and fluid retention minimized.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maximum recommended dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Mild-to-moderate heart failure:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &lt;85 kg: 25 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     &gt;85 kg: 50 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Severe heart failure: 25 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release:",
"     </i>",
"     Initial: 10 mg once daily for 2 weeks; if the dose is tolerated, increase dose to 20 mg, 40 mg, and 80 mg over successive intervals of at least 2 weeks. Maintain on lower dose if higher dose is not tolerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Left ventricular dysfunction following MI:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Should be initiated only after patient is hemodynamically stable and fluid retention has been minimized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     Initial 3.125-6.25 mg twice daily; increase dosage incrementally (ie, from 6.25-12.5 mg twice daily) at intervals of 3-10 days, based on tolerance, to a target dose of 25 mg twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release:",
"     </i>",
"     Initial: Extended release: Initial: 10-20 mg once daily; increase dosage incrementally at intervals of 3-10 days, based on tolerance, to a target dose of 80 mg once daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Angina pectoris (unlabeled use):",
"     </b>",
"     Oral:",
"     <i>",
"      Immediate release:",
"     </i>",
"     25-50 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Conversion from immediate release to extended release (Coreg CR&reg;):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Current dose immediate release tablets 3.125 mg twice daily: Convert to extended release capsules 10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Current dose immediate release tablets 6.25 mg twice daily: Convert to extended release capsules 20 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Current dose immediate release tablets 12.5 mg twice daily: Convert to extended release capsules 40 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Current dose immediate release tablets 25 mg twice daily: Convert to extended release capsules 80 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F146703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Refer to adult dosing. In the management of hypertension, consider lower initial doses and titrate to response (Aronow, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F146704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None necessary",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F146705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in severe liver dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F146669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as phosphate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coreg CR&reg;: 10 mg, 20 mg, 40 mg, 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Coreg&reg;: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F146653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F146673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with food to minimize the risk of orthostatic hypotension. Extended release capsules should not be crushed or chewed. Capsules may be opened and sprinkled on applesauce for immediate use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F146672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mild-to-severe heart failure of ischemic or cardiomyopathic origin (usually in addition to standard therapy); left ventricular dysfunction following myocardial infarction (MI) (clinically stable with LVEF &le;40%); management of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F146738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Angina pectoris",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F146750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Carvedilol may be confused with atenolol, captopril, carbidopa, carteolol",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Coreg&reg; may be confused with Corgard&reg;, Cortef&reg;, Cozaar&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F146740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Frequency ranges include data from hypertension and heart failure trials. Higher rates of adverse reactions have generally been noted in patients with heart failure. However, the frequency of adverse effects associated with placebo is also increased in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (9% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (2% to 32%), fatigue (4% to 24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia (5% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (1% to 12%), weight gain (10% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Bradycardia (2% to 10%), syncope (3% to 8%), peripheral edema (1% to 7%), generalized edema (5% to 6%), angina (1% to 6%), dependent edema (&le;4%), AV block, cerebrovascular accident, hypertension, hyper-/hypovolemia, orthostatic hypotension, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (5% to 8%), depression, fever, hypoesthesia, hypotonia, insomnia, malaise, somnolence, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia (1% to 4%), hypertriglyceridemia (1%), diabetes mellitus, gout, hyperkalemia, hyperuricemia, hypoglycemia, hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (2% to 9%), vomiting (1% to 6%), abdominal pain, melena, periodontitis, weight loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, prothrombin decreased, purpura, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased (1% to 3%), GGT increased, transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (2% to 7%), arthralgia (1% to 6%), arthritis, muscle cramps, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased (&le;6%), nonprotein nitrogen increased (6%), albuminuria, creatinine increased, glycosuria, hematuria, renal insufficiency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (5% to 8%), nasopharyngitis (4%), rales (4%), dyspnea (&gt;3%), pulmonary edema (&gt;3%), rhinitis (2%), nasal congestion (1%), sinus congestion (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Injury (3% to 6%), allergy, flu-like syndrome, sudden death",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactoid reaction, alopecia, angioedema, aplastic anemia, amnesia, asthma, bronchospasm, bundle branch block, cholestatic jaundice, concentration decreased, diaphoresis, erythema multiforme, exfoliative dermatitis, GI hemorrhage, HDL decreased, hearing decreased, hyperbilirubinemia, hypersensitivity reaction, hypokalemia, hypokinesia, interstitial pneumonitis, leukopenia, libido decreased, migraine, myocardial ischemia, nervousness, neuralgia, nightmares, pancytopenia, paresis, peripheral ischemia, photosensitivity, pruritus, rash (erythematous, maculopapular, and psoriaform), respiratory alkalosis, seizure, Stevens-Johnson syndrome, tachycardia, tinnitus, toxic epidermal necrolysis, urinary incontinence, urticaria, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F146676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious hypersensitivity to carvedilol or any component of the formulation; decompensated cardiac failure requiring intravenous inotropic therapy; bronchial asthma or related bronchospastic conditions; second- or third-degree AV block, sick sinus syndrome, and severe bradycardia (except in patients with a functioning artificial pacemaker); cardiogenic shock; severe hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F146657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers; causality has not been established and there appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery. Instruct patients to inform ophthalmologist of carvedilol use when considering eye surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope may occur with carvedilol (usually within the first 30 days of therapy); close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Initiation with a low dose, gradual up-titration, and administration with food may help to decrease the occurrence of hypotension or syncope. Patients should be advised to avoid driving or other hazardous tasks during initiation of therapy due to the risk of syncope.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormality: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms (eg, sweating, anxiety, tachycardia). In patients with heart failure and diabetes, use of carvedilol may worsen hyperglycemia; may require adjustment of antidiabetic agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure (HF): Heart failure patients may experience a worsening of renal function (rare); risk factors include ischemic heart disease, diffuse vascular disease, underlying renal dysfunction, and systolic BP &lt;100 mm Hg. In the severe chronic heart failure trials, patients were excluded if they had a baseline serum creatinine &gt;2.8 mg/dL or increasing serum creatinine. Initiate cautiously and monitor for possible deterioration in patient status (eg, symptoms of HF). Worsening heart failure or fluid retention may occur during upward titration; dose reduction or temporary discontinuation may be necessary. Adjustment of other medications (ACE inhibitors and/or diuretics) may also be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with mild-to-moderate hepatic impairment; use is contraindicated in patients with severe hepatic impairment. Manufacturer recommends discontinuation of therapy if liver injury occurs (confirmed by laboratory testing).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD): May precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud&rsquo;s disease; use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma (untreated): Adequate alpha-blockade is required prior to use of any beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disease: Use with caution in patients with a history of psychiatric illness; may cause or exacerbate CNS depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia. Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary but prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F146735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C9 (minor), CYP2D6 (major), CYP2E1 (minor), CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F146662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Alpha-/Beta-Blockers may diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Carvedilol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Carvedilol may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: May enhance the bradycardic effect of Carvedilol. Carvedilol may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F146692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Food decreases rate but not extent of absorption. Administration with food minimizes risks of orthostatic hypotension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid herbs with hypertensive properties (bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng [American], kola, licorice); may diminish the antihypertensive effect of carvedilol. Avoid herbs with hypotensive properties (black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, shepherd's purse); may enhance the hypotensive effect of carvedilol.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F146665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F146680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Because adverse events were not observed in animal reproduction studies, carvedilol is classified as pregnancy category C. In a cohort study, an increased risk of cardiovascular defects was observed following maternal use of beta-blockers during pregnancy. Intrauterine growth restriction (IUGR), small placentas, as well as fetal/neonatal bradycardia, hypoglycemia, and/or respiratory depression have been observed following",
"     <i>",
"      in utero",
"     </i>",
"     exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth should be available. Untreated chronic maternal hypertension and pre-eclampsia are also associated with adverse events in the fetus, infant, and mother. Carvedilol is not currently recommended for the initial treatment of maternal hypertension during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F146709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10162397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if carvedilol is excreted into human milk. The manufacturer suggests that a decision should be made to either discontinue nursing or discontinue the medication.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F146681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with food to minimize the risk of orthostatic hypotension.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F146679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Coreg CR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $175.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $175.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $175.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (30): $175.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Carvedilol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.125 mg (100): $213.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.25 mg (100): $213.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (100): $213.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $213.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Coreg Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.125 mg (100): $296.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.25 mg (100): $296.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12.5 mg (100): $296.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $296.45",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F146667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure (base need for dosage increase on trough blood pressure measurements and for tolerance on standing systolic pressure 1 hour after dosing); renal studies, BUN, liver function; in patient with increase risk for developing renal dysfunction, monitor during dosage titration.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F146682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alvelol (KP);",
"     </li>",
"     <li>",
"      Betacard (PH);",
"     </li>",
"     <li>",
"      Betaplex (CN);",
"     </li>",
"     <li>",
"      Blorec (ID);",
"     </li>",
"     <li>",
"      Caraten (TH);",
"     </li>",
"     <li>",
"      Carbloxal (ID);",
"     </li>",
"     <li>",
"      Cardilol (PH);",
"     </li>",
"     <li>",
"      Cardiol (FI, MY);",
"     </li>",
"     <li>",
"      Cardipres (PH);",
"     </li>",
"     <li>",
"      Cardivas (IN);",
"     </li>",
"     <li>",
"      Cargen (KP);",
"     </li>",
"     <li>",
"      Carloc (ZA);",
"     </li>",
"     <li>",
"      Carlov (PK);",
"     </li>",
"     <li>",
"      Carvedexxon (IL);",
"     </li>",
"     <li>",
"      Carvedil (EC);",
"     </li>",
"     <li>",
"      Carvedlol (KP);",
"     </li>",
"     <li>",
"      Carvelol (KP, NZ);",
"     </li>",
"     <li>",
"      Carvenal (KP);",
"     </li>",
"     <li>",
"      Carvepen (SG);",
"     </li>",
"     <li>",
"      Carveta (KP);",
"     </li>",
"     <li>",
"      Carvid (PH);",
"     </li>",
"     <li>",
"      Carvidil (RU);",
"     </li>",
"     <li>",
"      Carvidol (CL);",
"     </li>",
"     <li>",
"      Carvilar (DO);",
"     </li>",
"     <li>",
"      Carvo (TW);",
"     </li>",
"     <li>",
"      Cavedia (KP);",
"     </li>",
"     <li>",
"      Cavel (MY);",
"     </li>",
"     <li>",
"      Coreg (BB, BM, BR, BS, BZ, GY, JM, SR, TT);",
"     </li>",
"     <li>",
"      Coritensil (AR);",
"     </li>",
"     <li>",
"      Coryol (CO, CR, GT, NI, PA, SV);",
"     </li>",
"     <li>",
"      Dilasig (AU);",
"     </li>",
"     <li>",
"      Dilatrend (AR, AT, AU, BF, BG, BJ, BR, CH, CI, CN, CZ, DE, EC, EE, EG, ET, GH, GM, GN, GR, HK, HU, IT, KE, KP, LR, MA, ML, MR, MU, MW, MX, NE, NG, NO, NZ, PE, PH, PL, PY, SC, SD, SG, SL, SN, TH, TN, TR, TW, TZ, UG, UY, VE, ZM, ZW);",
"     </li>",
"     <li>",
"      Dilbloc (ID, PT);",
"     </li>",
"     <li>",
"      Dimitone (DK);",
"     </li>",
"     <li>",
"      Eucardic (GB, IE, NL);",
"     </li>",
"     <li>",
"      Karter (KP);",
"     </li>",
"     <li>",
"      Karvil (PH);",
"     </li>",
"     <li>",
"      Kredex (AU, BE, ES, FR, LU, NO, SE);",
"     </li>",
"     <li>",
"      Longcardio (TW);",
"     </li>",
"     <li>",
"      Nordiol (GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Querto (DE);",
"     </li>",
"     <li>",
"      Syntrend (TW);",
"     </li>",
"     <li>",
"      Talliton (BB, BM, BS, BZ, GY, HK, JM, SR, TT);",
"     </li>",
"     <li>",
"      Tocarlol (TH);",
"     </li>",
"     <li>",
"      Udilol (TW);",
"     </li>",
"     <li>",
"      V-Bloc (ID);",
"     </li>",
"     <li>",
"      Vasodilren (KP);",
"     </li>",
"     <li>",
"      Vasolexin (PH);",
"     </li>",
"     <li>",
"      Vedilol (KP);",
"     </li>",
"     <li>",
"      Wonvelol (KP);",
"     </li>",
"     <li>",
"      Xicard (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F146656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a racemic mixture, carvedilol has nonselective beta-adrenoreceptor and alpha-adrenergic blocking activity. No intrinsic sympathomimetic activity has been documented. Associated effects in hypertensive patients include reduction of cardiac output, exercise- or beta-agonist-induced tachycardia, reduction of reflex orthostatic tachycardia, vasodilation, decreased peripheral vascular resistance (especially in standing position), decreased renal vascular resistance, reduced plasma renin activity, and increased levels of atrial natriuretic peptide. In CHF, associated effects include decreased pulmonary capillary wedge pressure, decreased pulmonary artery pressure, decreased heart rate, decreased systemic vascular resistance, increased stroke volume index, and decreased right arterial pressure (RAP).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F146675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak antihypertensive effect: ~1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and extensive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 115 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;98%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic, via CYP2C9, 2D6, 3A4, and 2C19 (2% excreted unchanged); three active metabolites (4-hydroxyphenyl metabolite is 13 times more potent than parent drug for beta-blockade); first-pass effect; plasma concentrations in the elderly and those with cirrhotic liver disease are 50% and 4-7 times higher, respectively",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Immediate release: 25% to 35% (due to significant first-pass metabolism); Extended release: 85% of immediate release",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 7-10 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Extended release: 5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe DT, Armstrong PW, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(9):e82-292.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/15339869/pubmed\" id=\"15339869\" target=\"_blank\">",
"        15339869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brauchli YB, Jick SS, Curtin F, et al, &ldquo;Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2008, 158(6):1299-307.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/18410416/pubmed\" id=\"18410416\" target=\"_blank\">",
"        18410416",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bristow MR, Gilbert EM, Abraham WT, et al, &ldquo;Carvedilol Produces Dose-Related Improvements in Left Ventricular Function and Survival in Subjects With Chronic Heart Failure,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1996, 94(11):2807-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/8941106/pubmed\" id=\"8941106\" target=\"_blank\">",
"        8941106",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Colucci WS, Packer M, Bristow MR, et al, &ldquo;Carvedilol Inhibits Clinical Progression in Patients With Mild Symptoms of Heart Failure. U.S Carvedilol Heart Failure Study Group,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1996, 94(11):2800-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/8941105/pubmed\" id=\"8941105\" target=\"_blank\">",
"        8941105",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dargie HJ, &ldquo;Effect of Carvedilol on Outcome After Myocardial Infarction in Patients With Left-Ventricular Dysfunction: The CAPRICORN Randomised Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2001, 357(9266):1385-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/11356434/pubmed\" id=\"11356434\" target=\"_blank\">",
"        11356434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fleisher LA, Beckman JA, Brown KA, et al, &ldquo;2009 ACCF/AHA Focused Update on Perioperative Beta Blockade Incorporated Into the ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 54(22):e13-118.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/19926002/pubmed\" id=\"19926002\" target=\"_blank\">",
"        19926002",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juul AB, Wetterslev J, Gluud C, et al, &ldquo;Effect of Perioperative Beta-Blockade in Patients With Diabetes Undergoing Major Non-Cardiac Surgery: Randomized Placebo Controlled, Blinded Multicentre Trial,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 2006,  332(7556):1482.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/16793810/pubmed\" id=\"16793810\" target=\"_blank\">",
"        16793810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Macdonald PS, Keogh AM, Aboyoun CL, et al, &ldquo;Tolerability and Efficacy of Carvedilol in Patients With New York Heart Association Class IV Heart Failure,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 1999, 33(4):924-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/10091817/pubmed\" id=\"10091817\" target=\"_blank\">",
"        10091817",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer M, Bristow MR, Cohn JN, et al, &ldquo;The Effect of Carvedilol on Morbidity and Mortality in Patients With Chronic Heart Failure. U.S. Carvedilol Heart Failure Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(21):1349-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/8614419/pubmed\" id=\"8614419\" target=\"_blank\">",
"        8614419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer M, Coats AJ, Fowler MB, et al, &ldquo;Effect of Carvedilol on Survival in Severe Chronic Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 344(22):1651-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/11386263/pubmed\" id=\"11386263\" target=\"_blank\">",
"        11386263",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Packer M, Colucci WS, Sackner-Bernstein JD, et al, &ldquo;Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 1996, 94(11):2793-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/8941104/pubmed\" id=\"8941104\" target=\"_blank\">",
"        8941104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      POISE Study Group, Devereaux PJ, Yang H, et al, &ldquo;Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery (POISE Trial): A Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 371(9627):1839-47.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/18479744/pubmed\" id=\"18479744\" target=\"_blank\">",
"        18479744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Randomised, Placebo-Controlled Trial of Carvedilol in Patients With Congestive Heart Failure Due to Ischaemic Heart Disease. Australia/New Zealand Heart Failure Research Collaborative Group,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1997, 349(9049):375-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/9033462/pubmed\" id=\"9033462\" target=\"_blank\">",
"        9033462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Redelmeier D, Scales D, and Kopp A, \"Beta Blockers for Elective Surgery in Elderly Patients: Population Based, Retrospective Cohort Study,\"",
"      <i>",
"       BMJ",
"      </i>",
"      , 2005, 331(7522):932.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/16210252/pubmed\" id=\"16210252\" target=\"_blank\">",
"        16210252",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sch&ouml;n MP and Boehncke WH, &ldquo;Psoriasis,&rdquo;",
"      <i>",
"       N Eng J Med",
"      </i>",
"      , 2005, 352(18):1899-1912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/15872205/pubmed\" id=\"15872205\" target=\"_blank\">",
"        15872205",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      UK Prospective Diabetes Study Group, &ldquo;Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39,&rdquo;",
"      <i>",
"       BMJ",
"      </i>",
"      , 1998, 317(7160):713-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/9732338/pubmed\" id=\"9732338\" target=\"_blank\">",
"        9732338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yang H, Raymer K, Butler R, et al, &ldquo;The Effects of Perioperative Beta-Blockade: Results of the Metoprolol After Vascular Surgery (MaVS) Study, A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       Am Heart J",
"      </i>",
"      2006, 152(5):983-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/22/9577/abstract-text/17070177/pubmed\" id=\"17070177\" target=\"_blank\">",
"        17070177",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9208 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-90A40F4040-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_22_9577=[""].join("\n");
var outline_f9_22_9577=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146697\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146698\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146742\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146702\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146703\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146704\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146705\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146669\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146653\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146673\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146672\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146738\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146750\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146740\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146676\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146657\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146735\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146662\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146692\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146665\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146680\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146709\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10162397\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146681\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146679\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146667\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146682\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146656\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146675\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9208\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9208|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/15/37109?source=related_link\">",
"      Carvedilol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/63/40952?source=related_link\">",
"      Carvedilol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_22_9578="Reduction mastopexy";
var content_f9_22_9578=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Reduction mastopexy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 690px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reduction mastopexy lumpectomy.",
"    <br>",
"     (A) Skin incision design showing keyhole incision pattern.",
"     <br>",
"      (B) Initial skin incision.",
"      <br>",
"       (C) Manual examination of dissected tissues facilitating excision of specimen.",
"       <br>",
"        (D) Specimen excision.",
"        <br>",
"         (E) Fibroglandular defect after specimen excision.",
"         <br>",
"          (F) Wound approximation.",
"          <br>",
"           (G) Final wound closure.",
"           <br>",
"            (H) Postoperative result.",
"            <div class=\"footnotes\">",
"            </div>",
"            <div class=\"reference\">",
"             Reproduced with permission from: Calhoun KE, Anderson BO. Oncoplastic surgery: Segmental resection for lumpectomies. In: Master Techniques in General Surgery: Breast Surgery, Bland KI, Klimberg SV (Eds), Lippincott Williams and Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"            </div>",
"            <div class=\"contractual\">",
"             <br/>",
"             <a href=\"file://www.lww.com\">",
"              file://www.lww.com",
"             </a>",
"            </div>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_22_9578=[""].join("\n");
var outline_f9_22_9578=null;
var title_f9_22_9579="Foods that make UC worse PI";
var content_f9_22_9579=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F78463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F78463&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    List of foods that can make ulcerative colitis symptoms worse",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Milk, yogurt, cheese and other dairy products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coffee, tea, soda, and other foods that have caffeine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fruit and juice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fried, fatty, and spicy foods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Whole-grain and multigrain breads",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Condiments (such as ketchup or mustard) and salad dressings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Some vegetables, including cabbage, broccoli and cauliflower",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Red meat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Artificial colors, flavors and sweeteners",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_22_9579=[""].join("\n");
var outline_f9_22_9579=null;
var title_f9_22_9580="Urethral CA TNM women";
var content_f9_22_9580=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62556&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    TNM staging system for urethral cancer in women",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td>",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td>",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ta",
"      </td>",
"      <td>",
"       Noninvasive papillary, polypoid, or verrucous carcinoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       Carcinoma in situ",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       Tumor invades subepithelial connective tissue",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       Tumor invades periurethral muscle",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       Tumor invades anterior vagina, bladder neck",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4",
"      </td>",
"      <td>",
"       Tumor invades other adjacent organs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td>",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       Metastasis in a single lymph node 2 cm or less in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       Metastasis in a single node more than 2 cm in greatest dimension, or in multiple nodes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"2\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td>",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td>",
"       Distant metastasis",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_22_9580=[""].join("\n");
var outline_f9_22_9580=null;
var title_f9_22_9581="Felon";
var content_f9_22_9581=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55298&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Felon of the fingertip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 200px; height: 151px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The patient presented with three days of increased swelling, redness, and severe pain of the fingertip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anthony J Viera, MD. Copyright &copy; Anthony J Viera, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_22_9581=[""].join("\n");
var outline_f9_22_9581=null;
var title_f9_22_9582="Initial management of children with severe hypertension";
var content_f9_22_9582=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Initial management of children with severe hypertension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 293px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HF: heart failure; IV: intravenous; PO: oral.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Flynn, JT, Tullus, K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol 2008; Online first. Copyright &copy; 2008 Springer Science and Business Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_22_9582=[""].join("\n");
var outline_f9_22_9582=null;
var title_f9_22_9583="Charcot Leyden crystals";
var content_f9_22_9583=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71997&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Charcot-Leyden crystals",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Charcot-Leyden crystals as found in sputum from a patient with ascariasis. These crystals, which are found in all eosinophilic parasitic lung infections consist of lysophospholipase, an eosinophil- derived enzyme.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter F Weller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_22_9583=[""].join("\n");
var outline_f9_22_9583=null;
